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Sphingolipids are found in essentially all animals, plants and fungi, and some 
prokaryotic organisms and viruses. Sphingolipids function as structural components of 
membranes, lipoproteins, and as cell signaling modulators and mediators. To complicate 
matters further, sphingolipids often vary in type in different regions of tissues, and even 
in single cells, the subcellular localization of sphingolipids and their metabolic enzymes, 
transport proteins and targets may influence their functions. It is important to study 
sphingolipids spatial distribution within living organisms to understand how 
sphingolipids are involved in complex biochemical processes. 
As part of this thesis, procedures were optimized for the use of matrix assisted laser 
desorption/ionization (MALDI) tissue mass spectrometry (TIMS) to visualize the 
location of several types of lipids including sulfatides (ST), gangliosides and 
phosphoglycerolipids in brains from a mouse model for Tay-Sachs/Sandhoff disease. 
MALDI-TIMS was next applied to human ovarian carcinoma tissue to detect 
sulfatide location and established that ST are associated specifically with the regions of 
the ovarian tissue that bear the carcinoma. Electrospray ionization tandem mass 
spectrometry (ESI-MS-MS) was also used to confirm that ST and galactosylceramide 
(GalCer) are elevated in ovarian cancer. Gene expression data using tumor cells collected 
using laser capture microdissection revealed greater expression of mRNAs for GalCer 
synthase, GalCer sulfotransferase (Gal3ST1) and other enzymes of ST biosynthesis in 
epithelial ovarian carcinoma cells. This is a unique combination of two complementary, 
 
xviii 
profiling technologies--mass spectrometry (metabolomic approach) with analysis of gene 
expression to study complex cancer pathology. 
The next study focused on the subcellular location of sphingolipids. In comparison 
with wild type Hek293 cells, a Hek293 cell line stably overexpressing serine 
palmitoyltransferase (SPT1/2 cells) was found to have elevated amounts of all subspecies 
of ceramide (Cer), but produces disproportionately higher amounts of C18-Cer and GalCer.  
Since Cer is known to inhibit protein ER/Golgi trafficking, these studies found that the 
higher production of Cer caused impairment of ER/Golgi trafficking of Ceramide synthase 
1 (CerS1), thus increased C18-Cer. In addition, since GalCer is only synthesized in the 
lumen of the ER, this impairement of ER/Golgi trafficking also gave GalCer synthase 
access to its substrate and increased GalCer biosynthesis.   
These studies illustrate the complexity of sphingolipid biology and the usefulness of 






Sphingolipids are found in essentially all animals, plants and fungi, and some 
prokaryotic organisms and viruses. Sphingolipids function as structural components of 
membranes, lipoproteins, skin and other biomaterials, and as cell signaling modulators 
and mediators (1-3).  
 They are defined as a category by the presence of novel amine-containing lipid 
backbones (sphingoid bases: mainly sphingosine, sphinganine and phytosphingosine) to 
which can be attached amide-linked fatty acids and (or) a headgroup at the primary 
hydroxyl, which range in complexity from a simple -H in ceramide to highly complex 
glycoconjugates.   
 
1.1. Structural variation and nomenclature for sphingolipids 
The number of sphingolipid subspecies is not known, but there are hundreds of 
different combinations of sphingoid base backbones with amide-linked fatty acids, and 
over 400 different headgroup variations. The structural diversity of complex 
sphingolipids has been reviewed (4, 5) and addressed at a number of “omics” web sites, 
such as SphinGOMAP (www.sphingomap.org), the Japanese Lipid Bank 
(http://www.lipidbank.jp) and Glycoforum (http://www.glycoforum.gr.jp/), the Lipid 
Maps Consortium (www.lipidmaps.org), the Consortium for Functional Glycomics 
(http://www.functionalglycomics.org/fg/) and the Complex Carbohydrate Research 
Center at the University of Georgia (http://www.ccrc.uga.edu/~moremen/glycomics/). 
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The LIPID MAPS Consortium has recommended a systematic nomenclature (6) that is 
generally consistent with recommendations by the International Union of Pure and 
Applied Chemists and the International Union of Biochemists (IUPAC-IUB) (7) but also 
displays the compounds in a manner that is consistent with other lipid classes. 
 
1.1.1 Sphingoid bases 
 The 18-carbon sphingoid base shown in Fig. 1.1 has the chemical name (2S, 
3R,4E)-2--aminooctadec-4-ene-1,3-diol, but is commonly referred to as sphingosine (So).  
It would be named (E)-sphing-4-enine by the IUPAC nomenclature (7).  It is the major 
species found in most mammalian sphingolipids, followed by sphinganine (Sa) (which 
lacks the 4,5-trans-double bond) and 4-hydroxysphinganine( chemical name: 
(2S,3S,4R)-2-aminooctadecane-1,3,4-triol), which is often called phytosphingosine (8). A 
short-hand nomenclature for sphingoid bases gives the number of hydroxyl groups: d for 
the two (di-) hydroxyls of sphingosine and sphinganine, and t (tri-) for the additional 
hydroxyl in 4-hydroxysphinganine; followed by the chain length (typically 18 carbons); 
and the number of double bonds (0, 1 or sometimes 2); therefore, sphingosine is 




 The majority of the sphingoid bases in cells are N-acylated with long-chain or 
very-long-chain fatty acids to produce ceramides (Fig. 1.1). The fatty acids of ceramides 





Fig. 1.1. Basic structures of sphingolipid backbones and headgroups.  (A) An 
example of a ceramide backbone, including commonly used names and abbreviations for 
the components; (B) common headgroups attached directly to ceramide in mammalian 
sphingolipids, and (C) an example of a complex glycosphingolipid, ganglioside GM1a, 
and the names for the component parts.  (Modified from Y. Hirabayashi, Y. Igarashi, 





are mostly saturated), and presence or absence of a hydroxyl group on the α- or 
ω-carbon atom (1).  
The current convention is to use “ceramide” to denote N-acylsphingosines, 
dihydroceramides for N-acylsphinganines and 4-hydroxyceramides or phytoceramides 
for N-acyl-4-hydroxysphinganines. The fatty acyl chain length can be presented as a 
prefix, such as C18-Cer for N-stearoylsphingosine. When the sphingoid base is 
abbreviated, the nature of the fatty acyl chain is given after the type of sphingoid base; 
for example, N-stearoylsphingosine or C18-Cer is abbreviated d18:1/18:0. 
 
1.1.3. Glycosphingolipids 
 Most glycosphingolipids have a glucose or galactose attached to the 1-hydroxyl of 
Cer via a glycosidic bond in the β configuration.  More complex sphingolipids have 
additional carbohydrates. For mammals, the major neutral carbohydrates are glucose 
(Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine 
(GalNAc), and fucose (Fuc). Acidic glycosphingolipids contain ionized functional 
groups such as phosphate, sulfate (sulfatides), or charged sugar residues such as sialic 
acid or, less frequently, glucuronic acid. Sialic acids contain N-acetyl or N-glycolyl (i.e., 
hydroxyacetyl) groups at C5, and are named as N-acetylneuraminic acid (Neu5Ac) 
(structure shown in Fig. 1.1C) and N-glycolylneuraminic acid (Neu5Gc) respectively.   
 Despite the availability of so many building blocks and the possibility of 
theoretically millions of combinations, the number of compounds found in mammals is 
limited by the following observation: 1) Only Glc or Gal can be added directly to Cer to 
form glucosylceramide (GlcCer) or galactosylceramide (GalCer); 2) GalCer was 
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converted into a relatively small number of downstream metabolites, with the main 
products being sulfatides, which have a sulfate at the 3-position of the galactose; 3) Only 
a few immediate products from GlcCer can be formed and they are mainly 
lactosylceramide (LacCer) (Fig. 1.1C ); and, 4) A relatively limited number of tri- and 
tetra-hexosides from LacCer are produced and the products serve as so-called "root 
structures" for formation of more complex sphingolipids by further chain extension and 
branching (10, 11).  Even with these limitations, it has been estimated that there are 
over 500 headgroup variations (www.sphingomap.org) (4, 5), and more are likely to be 
found. 
Using glycosphingolipid nomenclature guidelines (7), one would name ganglioside 
GM1a):  Neu5Acα2-3(Galβ1-3GalNAcβ1-4)Galβ1-4Glcβ1Cer (d18:1/16:0), 
although the colloquial names assigned by the “ Svennerholm” system (14,15) are still in 
common usage, in which isomers are designated by additional letters, for example: 
   Galβ1-3GalNacβ1-4Galβ1-4Glcβ1-1’Cer  GM1a 
        | 
          Neu5Acα2-3 
 
  Neu5Acα2-3Galβ1-3GalNacβ1-4Galβ1-4Glcβ1-1’Cer GM1b 
These compounds can also be named using the root structure plus Roman 
numerals to show where the sialic acid (or other carbohydrate branchpoint) occurs along 
the chain, and Arabic superscripts to designate the hydroxyl- to which it is linked: 





-α-Neu5NacGg4Cer) for GM1b  
 
1.2. Biosynthesis of sphingolipids 
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De novo sphingolipid biosynthesis begins with the condensation of palmitoyl-CoA 
and L-serine to form 3-ketosphinganine (KDS), catalyzed by serine palmitoyltransferase 
(SPT) (12, 13). KDS is reduced to sphinganine (dihydrosphingosine) (14), which 
undergoes N-acylation by (dihydro)ceramide synthase(s) to dihydroceramides (15), and 
followed by desaturation to generate ceramides (16, 17) (18). These reactions are thought 
to occur on the cytosolic surface of the ER (14), followed by translocation from the ER to 
the Golgi apparatus (19) for the biosynthesis of most of the complex sphingolipids.  Cer is 
converted to SM by sphingomyelin synthase 1 (SMS1) on the lumenal side of the Golgi or 
SMS2 at the plasma membrane (20), or glycosylated to GlcCer or GalCer (the latter 
occurring in the lumen of the ER) (21-23), which are the precursors for all complex 
glycosphingolipids of mammals (1) (Fig. 1.2).  
 
1.2.1 Biosynthesis of ceramide 
Ceramide is highly insoluble in aqueous medium. To deliver the Cer or Cer analog 
into cells, potentially disruptive detergents, liposomes, or organic solvent mixtures have 
to be used (21). This water insolubility is used biologically because Cer is about one 
third of the total lipid in the skin and participates in the water barrier of skin. Also, Cer 
tends to form dynamic aggregates in biological membranes, thus it is able to participate 
in the formation of rafts and caveolae, and can affect membrane curvature (3).  
In cell signaling, Cer (often studied, however, using shorter chain analogs) is able 
to induce a large number of cellular responses through multiple protein targets.  For 
examples: 1) Phosphoprotein Phosphatases 1 and 2A are activated by Cer and perform 






Fig. 1.2. De novo sphingolipid biosynthesis highlighting the branching of the 
pathway at acylation of sphinganine by ceramide synthases. Starting at the top is the 
biosynthesis of sphinganine, which can be acylated by the ceramide synthases shown 
with their fatty acyl-CoA preference. The abbreviation shows the sphingoid base 
backbone using the abbreviated nomenclature of Fig. 1.1 followed by the alkyl-chain 
length and number of double bonds of the fatty acid. Each dihydroceramide (DHCer) can 
be desaturated to the comparable ceramide (Cer) and both have several possible fates, as 
illustrated seperately: conversion to (dihydro)ceramide-1-phosphate, (DH)CerP; 
(dihydro)sphingomyelin, (DH)SM; (dihydro)glucosylceramide, (DH)GlcCer; 
(dihydro)galactosylceramide, (DH)GalCer; or hydrolysis to the free sphingoid base, that 
can be phosphorylated (SaP and SoP). Not shown are DES2 is capable of hydroxylating 
the 4-position to form 4-hydroxydihydroceramides, t18:0 (phytoceramide). (DH)GalCer 
are further converted into (DH)sulfatide ((DH)ST); (DH)GlcCer are converted into more 
complex glycosphingolipids. (DH)ST and complex glycosphingolipids from DHGlcCer 




the PKC family are affected by Cer. Cer promotes phosphorylation and translocation of 
PKCα, PKCδand PKCε (24, 25) but inhibits the juxtanuclear translocation of PKCβ2 
(26). PKCξ is activated by the direct binding of Cer, which leads to the formation of a  
proapoptotic complex with prostate apoptosis response-4 (PAR4) (27); 3) Cer binds to 
cathepsin D when this protease was isolated by Cer affinity chromatography (28) and 
production of Cer by acid sphingomyelinase (a-SMase) in response to TNFα, CD95, and 
chemotherapeutic agents (29) activates cathepsin D to induce caspase-independent 
apoptosis; 4) It has also been reported that Cer directly binds to activate stress activated 
protein kinase (SAPK/JNK) and induces glomerular epithelial cells to undergo apoptosis 
(30). 
 
1.2.1.1. Synthesis of the N-acyl-derivatives of sphingoid bases 
As shown in Fig. 1.2, sphinganine is acylated to dihydroCer by a family of Cer 
synthases (CerS, previously referred to as Lass).There are six mammalian ceramide 
synthases which all have five conserved predicted transmembrane α-helices referred as 
the TLC (TRAM-Lag1-CLN8) domain (15). The ceramide synthases have different 
preference for different fatty acid chain (15, 31-34) (Fig. 1.2). All of mammalian Cer 
synthase genes except CerS1 contain a HOX domain, a transcription factor involved in 
developmental regulation (15). 
The genes required for Cer synthase activity were initially found in yeast. CerS1 is 
the first mammalian gene was discovered that encoded a Cer synthase, and it was 
noteworthy that it was highly selective for stearoyl-CoA and formation of C18-(dihydro) 
Cer (34).  Subsequent studies have found that the other CerS are also selective for other 
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fatty acyl-CoAs and in varying degrees (33, 35).  A summary of current thinking about 
the steps of this pathway is shown in Fig. 1.2. Cer can also be made by reversal of 
ceramidase, however, this reaction appears to account for relatively little Cer synthesis 
under normal physiological conditions (36). 
Ceramide synthase was first purified from yeast and in doing so, a new subunit, 
Lip1, was identified. Lip1 is a single-span membrane protein located in the endoplasmic 
reticulum that is required for ceramide synthesis in vivo and in vitro in yeast (37, 38).  
But homology searches of mammalian gene databases have not revealed any mammalian 
genes that have Lip1 function (15).  Mammalian CerS5 has been purified to 
homogeneity and retains its specificity for palmitoyl-CoA and does not require any 
additional subunits for activity (39).   
Although relatively little is known about the regulation of CerS, there have been a 
number of interesting findings about how they appear to be regulated.  Expression of 
the CerS genes in human embryonic kidney cells has powerful effects on the sensitivity 
of the cells to different drugs used in cancer chemotherapy (40). CerS1 sensitizes cells to 
a wide range of drugs, including cisplatin, carboplatin, doxorubicin and vincristine, 
whereas CerS5 only sensitizes cells to doxorubicin and vincristine, and CerS4 does not 
affect sensitivity to any of the tested drugs (40) . CerS1 has been found to have a short 
half-life, and is turned over by ubiquitination and rapid proteasomal degradation, with 
CerS1 turnover regulated by the opposing functions of p38 MAP kinase and protein 
kinase C (PKC) (44, 45).  p38 MAP kinase is a positive regulator of turnover, while 
PKC is a negative regulator of turnover (41).  CerS1 apparently undergoes cleavage to a 




Ceramide biosynthesis de novo is thought to occur in the ER, where all the 
participating enzymes have been found (14, 42, 43). Cer are synthesized at the cytosolic 
side of the ER (14) and then serve as a precursor for the biosynthesis of 
glycosphingolipids and SM in the Golgi (44, 45).  
Nonetheless, the mitochondrion is also beginning to be viewed as another 
important site of ceramide metabolism because mitochondria contain a variety of 
sphingolipids, including SM and Cer (46, 47) and there is also CerS activity in 
mitochondria (48) and a mitochondria–enriched fraction (49).  Analysis of CerS activity 
in highly purified mitochondria has supported these findings (55-57). A report also 
suggests that Cer could be transported from the ER to mitochondria through the contact 
sites between the ER and mitochondria (50).  Cer has an important effect on 
mitochondria, whether produced there or transported from there ER—to induce 
mitochondrial apoptosis. Cer increases are implicated in apoptosis in response to 
CD95/Fas, TNFα, and radiation (51), and many hallmarks of regulation of apoptosis 
have been linked to Cer, including Akt dephosphorylation, mitochondrial depolarization 
and permeabilization, cytochrome c release and activation of caspase-3 (52), formation 
of Bax homodimers (53) and suppression of respiratory chain activity at complex III 
and/or complex I (54, 55) resulting in increased production of ROS (54-57), well-known 
inducers of apoptosis.  
Cer biosynthesis is clearly important for organisms because ceramide synthases 
are the target of a family of mycotoxins that cause a wide range of diseases of 
agricultural animals, humans, and plants.  These mycotoxins are called fumonisins and 
 
 11 
are produced by Fusarium verticillioides (formerly F. moniliforme), which is a frequent 
contaminant of maize (58). The most prevalent subspecies is fumonisin B1 (FB1), which 
is comprised of a long chain aminopentol (AP1) that has many structural similarities to 
sphinganine, and two ester-linked tricarballylic acids (59).  Thus, fumonisins inhibit 
CerS by acting as substrate analogs (i.e., as 1-deoxy-analogs of sphinganine) (60).  
The Cer subspecies is also very important.  C16-Cer is thought to be particularly 
important in apoptosis (69-71), and C18-Cer has been found to be abnormally low in 
head and neck cancer—apparently due to lower expression of CerS1 (61). 
 
1.2.1.2. Desaturation and hydroxylation of dihydroceramide to form ceramides and 
4-hydroxyceramides (phytoceramides) 
 The last step of Cer biosynthesis is insertion of the 4,5-trans-double bond into the 
sphingoid base backbone, which occurs at the level of dihydroCer (Fig. 1.2) (18) which 
is catalyzed by two mammalian gene products (DES1 and DES2).  When expressed in 
mammalian cells, DES1 appears to have only desaturase activity whereas DES2 can 
perform both desaturation and 4 hydroxylation (62, 63).  
 
1.2.2. Biosynthesis of more complex sphingolipids 
 In mammals, Cer is at the branchpoint for biosynthesis of four major compounds: 
the two phosphosphingolipids, sphingomelin (SM) and Cer 1-phosphate (Cer-P) and two 
glycosphingolipids, galactosylceramide (GalCer) and glucosylceramide (GlcCer), which 
are the precursors of hundreds of complex glycosphingolipids (4, 5).  Mammalian cells 
also make ceramide phosphoethanolamine (64, 65), but this is present in trace amounts 
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and has been suggested to have a role in regulating sphingolipid metabolism rather than 
other sphingolipid structure/functions.  
 
1.2.2.1. Sphingomyelin and Ceramide 1-Phosphate 
Sphingomyelin is synthesized by transfer of phosphorylcholine from 
phosphatidylcholine to Cer by both SM synthases, SMS1 localized to the Golgi, and 
SMS2 in the plasma membrane (20). The sequences of SMS1 and SMS2 suggest that 
they are integral membrane proteins with multiple membrane-spanning core domains 
(66). Characterization of cloned SMS1 and SMS2 has confirmed that they function as 
bi-directional lipid choline phosphotransferases capable of converting 
phosphatidylcholine and Cer into SM and diacylglycerol and vice versa. 
Ceramide 1-phosphate (Cer-P) is also made in the Golgi by ceramide kinase 
(CERK). Human CERK was clone from Jurkat acute T-cell leukemic cells in 2002. It 
encodes a protein of 537 amino acids which has a catalytic region with a high degree of 
similarity to the diacylglycerol kinase catalytic domain. It has a putative 
N-myristoylation site followed by a pleckstrin homology (PH) domain on N- terminus 
and contains a calcium/calmodulin binding motif on C-terminus (67). CERK is the only 
verified source of Cer-P in mammalian cells. In certain types of spider, hydrolysis of 
sphingomyelin by sphingomyelinase D can also produce Cer-P. Surprisingly, in CERK 
knock-out mice, total cellular levels of Cer-P in cerebellar purkinje cells were not 
different compared to cells from wild-type mice. This suggested further study for the 
presence of other Cer-P-producing pathway (68). 
Both SMS1 and CERK require that Cer be delivered to the Golgi, which has been 
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shown to involve a Cer transport protein (CERT) since Cer are synthesized on the 
cytosolic ER while all complex sphingolipids, with the exception of GalCer (69), are 
synthesized at the Golgi and plasma membrane (45, 70, 71). Studies showed that Cer is 
transported from the ER to the Golgi site for the synthesis of SM through a CERT 
mediated the ATP-dependent pathway in a nonvesicular manner (19, 72, 73).  CERT 
efficiently transfers Cer with fatty acids with chain lengths C14 to C20, but not longer acyl 
chains, and also mediates the transfer of C16-dihydroceramide and C16-phytoceramide 
(74). 
CERT is a hydrophilic 68-kDa protein that is envisioned to have three important 
functional regions (72).  The amino terminal ~120 amino acid region contains a PH motif, 
which is a phosphoinositide-binding domain (75);  the carboxyl terminal ~230 amino acid 
region forms a putative lipid-transfer domain, START (76);  and the middle region (MR) 
is predicted to have a short motif that interacts with the ER. Thus, these domains allow 
CERT to extract Cer from the ER and deliver it to the Golgi apparatus and, possibly, after 
release of ceramide at the Golgi apparatus, CERT might in turn bind diacylglycerol 
generated during SM synthesis and carry it to the ER where many phosphoglycerolipids 
are made.  This may not involve movement of CERT through the cytosol per se because 
subdomains of the ER are suggested to be spatially very close (~10 nm) to trans Golgi, 
thus, the PH domain and the FFAT motif of CERT might simultaneously associate with 
the Golgi apparatus and the ER, respectively, and the pickup and delivery of ceramide 
from the ER to the Golgi apparatus might be attained by the ‘neck-swinging’ movement of 
the START domain (72).  When CERT is phosphorylated, there is an auto-inhibitory 
interaction between the PH and START domains that inactivates both the 
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phosphoinositide-binding and Cer transfer.  Loss of SM and cholesterol from cells 
causes dephosphorylation of CERT, thereby activating Cer transport and restoring SM 
biosynthesis (77).  
In addition to non-vesicular transport, yeast genetic studies have demonstrated the 
participation of COPII components in Cer transport to the Golgi site of 
inositolphosphorylceramide (IPC) synthesis (78). The mechanism of how ceramide is 
delivered to the Golgi via vesicular transport is not yet clear, but it is thought that there 
may be a selective transport process for Cer. 
 
1.2.2.2 Glycosphingolipids 
Glycosphingolipids are found in all cells of vertebrates. They are generally thought 
of as components of the plasma membrane, and in particular of sub-regions of the plasma 
membrane termed “rafts,” but they are also found in other organnels including the 
mitochondria (79) and nuclei (80).  Glycosphingolipids participate in cell adhesion and 
cell-cell communication by binding to proteins and carbohydrates from the extracellular 
matrix (81) and cells (82) .  This not only provides structure and organization, but can 
modulate the activities of membrane receptors on neighboring cells or the same 
membrane (83, 84). 
 The biosynthesis of the hundreds of glycosphingolipids is using surprisingly few 
glycosyltransferases (GTs) which commit precursors and intermediates to predictable 
products based on the specificities of the enzymes (www.sphingomap.org) (5). 
Glycosyltransferases normally transfer a specific sugar residue from the appropriate 
sugar nucleotide (e.g., UDP-Glc, UDP-Gal, CMP-sialic acid) to Cer or to the 
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non-reducing end of the carbohydrate chain attached to Cer. Many GT genes have been 
identified by molecular cloning or homology search of the available genomic databases 
and have been classified into families by amino-acidsequence similarities (85)(available 
at http://www.cazy. org/fam/accGT and http://glycob.oupjournals.org). 
GlcCer synthase (UDP-Glc:Cer glucosyltransferase, CGlcT) (86) has been cloned 
and mapped to 9q31 in humans and 4B3 in mice (87, 88). It is located on the cytosolic 
side of the Golgi (89, 90) and consists of a strongly hydrophobic Golgi anchor segment 
near the N-terminus (88) and a catalytic C-terminal located in the cytoplasm (89). 
GlcCer synthase mRNA is ubiquitously expressed across cell types, suggesting that it is 
essential for cellular function, and GlcCer synthase knock out is embryonic lethal; 
embryonic cells were able to proceed into primitive stages of cell division/differentiation, 
but ultimately did not survive (91). However, it has not been noted to be required for cell 
growth in cell culture (92).  
It is revealed that the expression of GlcCer synthase is regulated by a lot of factors, 
such as depletion of the amounts of GlcCer in the cell (93, 94), elevations in Cer (95), 
endotoxin and acute phase response mediators (96), and doxorubicin (97). GlcCer and 
protein-bound GlcCer are both involved in establishing the permeability barrier of skin, 
and GlcCer synthase is up regulated during epidermal barrier development (98-100). 
 The synthesis of GlcCer is inhibited by analogs of Cer (101). Studies show 
analogs of Cer decrease cellular levels of neutral glycosphingolipids and gangliosides 
(and elevation of Cer), and finally cause cell cycle arrest (102). GlcCer synthesis is also 
influence survival of tumor cells (103-105).  
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GalCer is synthesized in the lumen of the ER by GalCer synthase (UDP-Gal:Cer 
galactosyltransferase, CGalT) (106, 107). GalCer synthase contains an ER retrieval 
signal (KKVK) at the C-terminus. The N-terminus faces the lumen of the ER and  
contains the active site (106). The substrates for GalCer synthase are thought to be made 
available by a transporter for UDP-Gal, the UDP-Gal transporter 2 (UGT2), a splice 
variant of UGT1 (the transporter for UDP-Gal into the Golgi) that contains an ER 
locating dilysine motif (KVKAS) (69), and for Cer by the rapid flip-flop of this molecule 
across the ER membrane (108). 
Relatively little is known about the regulation of GalCer biosynthesis. GalCer 
synthase is highly expressed in oligodendrocytes and Schwann cells, with a pattern that 
matches that of myelination (109). Therefore, it might be hypothesized that a major 
determinate of the amounts of GalCer in cells is whether or not they express the gene and 
protein for GalCer synthase.  As will be shown in Chapter 4 of this thesis, we have 
found that the situation is more complicated.  
GalCer synthase is required for normal function because deficient mice display 
hind limb paralysis, tremors, ataxia, and vacuolization of the ventral region of the spinal 
cord (110). Interestingly, in the absence of GalCer, this monohexosylceramide was 
replaced by higher than usual amounts of GlcCer and a non-commonly encountered 
glycolipid, GlcCer-sulfate. These are unable to fully substitute, however, because these 
mice demonstrate electrophysiological defects with histological correlates of impaired 
oligodendrocyte differentiation, unstable myelin sheaths, and nodal and paranodal 
structural abnormalities (110). 
 
 17 
 GalCer is the major glycolipid for biosynthesis of the so-called sulfatides: 
3'-sulfo-Galβ1-1'Cer (GalCer-I3-sulfate), which is the major sulfoglycolipid of brain, 
kidney, the gastrointestinal tract and endometrium, and mammalian male germ cells, and 
some higher order glycolipids.  Sulfatide biosynthesis is catalyzed by GalCer 
sulfatotransferase (sulfatide synthase), which utilizes the activated sulfate donor 
3'-phosphoadenosine-5'-phosphosulfate (111). The cDNA encoding the sulfotransferase 
has been cloned (111). GalCer sulfotransferase-null mice showed some neurological 
disorders due to myelin dysfunction, an aberrant enhancement of oligodendrocyte 
terminal differentiation, and an arrest of spermatogenesis, indicating that sulfation of 
glycolipids is essential for myelin formation and spermatogenesis (112, 113). Moreover, 
GalCer sulfatotransferase-deficiency ameliorates L-selectin-dependent monocyte 
infiltration in the kidney after ureteral obstruction, which suggests that sulfatide is an 
endogenous ligand of L-selectin (114).  
Sulfatides expressed on cell surfaces of different cells exert biological functions 
through mediating interactions with various proteins, such as laminin, thrombospondin, 
amphoterin, selectins, galectin, and hepatocyte growth factor (115-118) (119, 120). Some 
of these proteins are adhesion molecules that are involved in cell–cell and 
cell–extracellular matrix interactions. Selectins and laminin are thought to be involved in 
metastasis (116, 117, 121). 
 
1.3. Sphingolipid catabolism 
In general, sphingolipids are internalized with endocytic vesicles, sorted in early 
endosomes, and recycled back to the plasma membrane (often with remodeling of the 
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sphingolipid) (122) or transported to lysosomes where they are degraded by specific acid 
hydrolases (123). The membrane sphingolipids also can be turnover to release bioactive 
products, such as sphingoid bases, SoP, SaP, or Cer, which are involved in cell signalling. 
SoP and SaP can be secreted through plasma membrane to extracellular enviroment. 
The major pathways for sphingolipid catabolism are summarized in Fig. 1.3.  It is 
noteworthy that most of the steps have been associated with genetic diseases, except for 
the hydrolysis of LacCer, which is due to the presence of two enzymes each of which can 
cleave that glycosphingolipid.  
 
1.3.1.  Sphingomyelin 
The hydrolysis of SM to Cer and phosphocholine is catalyzed by 
sphingomyelinases (SMase). According to their optimum pH, SMase isoforms can be 
divided into three groups: alkaline, acidic, and neutral SMases, and are further sub 
classified by their primary structure, localization, and cation dependence. Alkaline 
SMase (alk-SMase) is present in the intestinal tract and additionally human bile. It 
hydrolyses sphingomyelin in both intestinal lumen and the mucosal membrane in a 
specific bile salt dependent manner (124). Neutral SMases are found in multiple cellular 
compartments, including the plasma membrane, the nuclear membrane, ER (125). Two 
major neutral SMases have been cloned --nSMase1 and nSMase2 and they are thought to 
participate in cell signaling; for example, nSMase2 in mammalian cells is active in 
inflammation, apoptosis and cell growth (125-127). Acidic SMase (ASMase) has two 





Fig. 1.3. Catabolism of complex sphingolipids and diseases associated with 
deficiencies in the enzymes. (Modified from T. Kolter and K. Sandhoff, 2006) 
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gene (designated Smpd1). ASMase is a water-soluble glycoprotein that interacts with a 
sphingolipid activator protein (SAP) and anionic lipids to hydrolyze SM (128).  Acid 
SMase also possesses an N-terminal SAP-homology domain that appears to stabilize the 
correctly folded form of acid SMase as well as to facilitate the interfacial interaction 
with substrate in vivo (129).  
Defects in the acid SMase gene (Smpd1) result in Niemann-Pick disease types A 
and B. Patients with type A develop severe neurological and visceral pathology and died 
before 3 years of age; while patients with type B can survive into adolescence or early 
adulthood, and characteristically do not manifest neurological signs or symptoms. 
Individuals with either form display accumulation of SM in reticuloendothelial cells 
scattered throughout the spleen, bone marrow, lymph nodes, liver, and lungs. The 
severity of the disease has sometimes been related to the nature of the genetic defect (130, 
131) and the level of residual lysosomal SMase activity (132). Sphingomyelin also 
accumulates in Niemann-Pick disease type C but is not due to genetic defects in SMase 
per se but to defects in the NPC-1 and -2 genes, which encode proteins involved in 
cholesterol trafficking and mutation of either of these proteins results in massive 
accumulation of cholesterol in perinuclear lysosomes (133). The influence of cholesterol 
species on aSMase activity and subsequent biology is still under investigation. 
 
1.3. 2. Glycosphingolipids 
Glycosphingolipids are catabolized by the stepwise hydrolysis of the terminal 
monosaccharides through the concerted action of a series of specific exoglycosidases 
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(Fig. 1.3) (123). There is often a requirement for sphingolipid activator proteins, 
comprised by SAP-A, -B, -C or –D, and GM2-activator protein.  
 A number of inherited diseases are caused by mutations in either the structural 
genes encoding these enzymes or activator proteins (Fig. 1.3).   
Gaucher disease is a storage disease in which accumulation of GlcCer occurs, 
specifically in cells of macrophage lineage macrophage. It arise from defective 
β-glucosidase and is inherited in an autosomal recessive fashion (134) (Fig. 1.3). 
β-Glucosidase is allosterically activated by Sap-C and responsible for cleaving GlcCer 
intoβ-glucose and ceramide subunits (135).  
Three different types of Gaucher disease are distinguished. The 2 major forms are 
non-neuropathic (type I, the most frequent form in adulthood) and neuropathic (type II 
and III). Gaucher disease type I has an accumulation of glucosylceramide within cells 
(especially in the macrophages) of the reticuloendothelial system (mainly spleen, liver, 
and bone marrow). The aggregation of glucosylceramide within the lysosomes of the 
cells prevents their destruction, and results in their enlargement into “Gaucher cells” and 
therefore causes the organ damage. In contrast, type II is an acute neuronopathic form 
with lifespan of 2 to 3 years and has severe, progressive neurologic problems. Type III, 
the subacute or juvenile form, is intermediate with a later onset and a slower 
development of the neurological symptoms than type II and lifespan of the patients is 
between a few years and four decades (134) . 
Approximately 200 mutations at the β- glucosidase locus have been found in 
patients with Gaucher disease. N370S, L444P, RecNciI, 84GG are four most common 
mutations (136). Very rarely, Gaucher disease is caused by the absence of a sphingolipid 
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activator protein, Sap-C (137, 138). 
The standard therapy for adult Gaucher disease is enzyme replacement therapy 
(ERT) (combination of alglucerase and imiglucerase) (139) and substrate reduction 
therapy (SRT) with N-butyl-deoxynojirimycin (NB-DNJ) or miglustat to reduce the 
formation of glucosylceramide by inhibiting the glucosylceramide synthase enzyme 
(140). 
Krabbe disease, also called globoid cell leukodystrophy, is an autosomal recessive 
disorder with the accumulation of GalCer due to defective β-galactosidase (141) (Fig. 
1.3). Sap-A and Sap-C are able to stimulate β-galactosidase in vivo (142, 143). Because 
GalCer synthase is active in white matter during myelination in mammals and GalCer 
and ST are major comonents in myelin, the pathological consequences of the 
β-galactosidase deficiency are almost exclusively confined to the white matter of the 
central and peripheral nervous systems (CNS, PNS) (144-146).  
Clinically, Krabbe disease has three variants: the infantile type, juvenile type and 
adult type which are subclassified by the onset and severity of clinical symptoms. 
Krabbe disease is most often diagnosed in infants before 1 year of age because of their 
early onset of developmental delay, limb stiffness, and extreme irritability (147, 148). 
The disease progresses rapidly and most patients die before 2 years old. Individuals of all 
ages diagnosed with Krabbe disease show white matter changes on magnetic resonance 
imaging (MRI), weakness, loss of skills, and onset of vision loss (149, 150).  
The pathogenesis of this disease can be attributed to accumulation of GalCer and 
its cytotoxic derivative galactosylsphingosine. The accumulation of GalCer leads to 
globoid cell infiltration, and the accumulation of galactosylsphingosine induces 
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apoptosis and causes oligodendroglial cell death, which consequently results in 
demyelination (151-153). Over 60 mutations have been identified in the 
humanβ-galactosidase gene (141). A deletion of exons 11–17 is a very frequent mutation 
and makes up about 40–45% of the mutant alleles in infantile patients in northern Europe 
(154, 155). 
Hematopoietic stem cell transplantation is considered effective for juvenile Krabbe 
disease if early diagnosis is possible (156). 
The GM2 gangliosidoses are autosomal recessive, lysosomal storage diseases 
resulting from an inability to catabolize GM2 ganglioside and related glycolipids due to 
mutations in the α or β subunits of hexosaminidases A, B, or of the GM2 activator 
protein. Hex A is an heterodimer with both α and β subunits that degrades negatively 
charged and uncharged substrates, whereas Hex B is the ββ-homodimer that cleaves 
mainly N-acetylgalactosamine residues from uncharged substrates such as GA2, 
globotetraosylceramide and oligosaccharides (123, 157, 158) (Fig. 1.3). Therefore, Tay 
Sachs disease (A variant) has mutations in the gene for the α subunit which result in 
partial or complete loss of Hex A activity, but not Hex B; Sandhoff disease (B variant) 
has mutations in the gene for the β subunit which affect both Hex A and Hex B; The 
third form, GM2 activator deficiency (AB variant), is due to the mutations in GM2A 
gene. So it is easy to distinguish Tay-Sachs disease and Sandhoff disease by measuring 
Hex A and Hex B activities and by the accumulation of GA2 in Sandhoff disease but not 
in Tay-Sachs disease. The AB variant has normal Hex A, B activity in vitro, but has a 
defective GM2 activator protein.  
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The phenotypes of these gangliosidoses are similar. The infantile forms, caused by 
the total absence of Hex A, are rapidly progressing neurodegenerative disorders resulting 
in death in early childhood. The later-onset forms I (juvenile or adult forms), 
characterized by low but detectable level of Hex A activity, progress more slowly and 
may display a spectrum of clinical manifestations including ataxia, spinocerebellar 
degeneration, motor neuron disease and the muscle wasting.   
 Mouse models are available for Tay-Sachs disease (α-chain deficiency, hexa 
-/-
), 
Sandhoff disease (β-chain deficiency, hexb 
-/-
) and GM2 activator deficiency (159). 
Tay-Sachs disease mice suffer no obvious behavioral or neurological deficit, while 
Sandhoff disease mice develop a fatal neurodegenerative disease. The severity and 
course of the disease differs may be due to species differences in the sialidase activity of 
the mouse versus human. Tay-Sachs disease mice escape disease through partial 
catabolism of accumulated GM2 via GA2 by the combined action of sialidase and Hex B 
(160). 
The molecular pathogenesis of brain injury of these diseases is not fully 
understood. However, the inflammatory response involving macrophage/microglial cells 
might be important because activated microglial expansion was found to precede 
massive neuronal death and is suppressed by bone marrow transplantation in sandhoff 
disease mice (161). Studies have revealed that elimination of macrophage-inflammatory 
protein 1α expression resulted in a substantial decrease in macrophage/microglial cell 
infiltration and pathology, and reduced neuronal apoptosis. Furthermore, the Sandhoff 
disease mice showed improved neurologic status and a longer lifespan (162).  
Currently, there is no treatment for GM2 gangliosidosis. A Sandhoff mouse model 
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have been very useful for therapies based on the transfer of genes or cells into the 
nervous system, such as bone marrow transplantation (161), injection of vector encoding 
the Hex A alpha-subunit in vivo (163) and stereotaxic intracranial inoculation of 
adeno-associated viral vectors with the complementing β-hexosaminidase A (164). 
 
1.3.3 Ceramide 
In lysosomes, Cers are hydrolyzed to free sphingoid bases and long-chain fatty 
acids by a ceramidase that has an acidic pH optimum.  The lysosomal acidic ceramidase 
is a water soluble glycoprotein that hydrolyzes membrane-bound Cer in an interfacial 
reaction that requires stimulation by SAP-C or -D (165). The human acidic ceramidase is 
a heterodimer of 40 kDa and 13 kDa subunits which are synthesized by self cleavage 
from a single precursor polypeptide and targeted to the lysosome via the mannose 
6-phosphate receptor (166) (167).    
A genetic deficiency in acidic ceramidase activity causes an accumulation of 
sphingolipids in lysosomes and lead to a lysosomal storage disorder, Farber disease 
(168).  
An additional four ceramidases (neutral ceramidase, alkaline ceramidase 1, 2, 3) 
from distinct genes have been cloned (167, 169).  Alkaline ceramidase1–3 have similar 
protein sequences but have no homology to either acidic or neutral ceramidase. They are 
located in various cell compartments (plasma membrane, ER and Golgi) and appear to be 
involved in signaling (166, 170, 171) (169).   
 
1.4 Perspectives and future directions 
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Previously sphingolipids have been analyzed by a variety of methods, such as 
thin-layer chromatography, immunochemistry, radiolabelling, etc (172) (173-176). 
However, there are limits to the specificity of these methods and to the number of target 
compounds which can be monitored simultaneously. Many of sphingolipid species are 
metabolically interrelated and highly bioactive. Methods for quantitive analysis of 
multiple species in biological samples are needed. With use of the tandem mass 
spectrometry methods in our lab, one can detect a variety types of sphingolipids, from 
sphingoid base, sphingoilipids backbone—ceramide to complex sphingolpids (SM, 
GalCer, GluCer, ST, et al) (177-179).  
Furthermore, sphingolipids often vary in the types of sphingolipids in different 
regions of tissues, and even when analyzing single cells, the subcellular localization of 
sphingolipids and their metabolic enzymes, transport proteins and targets may influence 
their function just as mentioned earlier in this chaper. Understanding the complex 
biochemical processes that occur within living organisms requires not only the 
elucidation of the molecular entities involved in these processes, but also their spatial 
distribution within the organism.  
Imaging mass spectrometry is an emerging powerful technology to identify 
various molecules and determine their spatial distributions directly in biological samples 
(2, 180-182). Therefore, in chapter 2, we developed an improved method for studying 
sphingolipids in tissues using matrix-assisted laser desorption/ionization (MALDI) tissue 
imaging mass spectrometry (TIMS).  A mouse model of Tay-Sachs and Sandhoff 
disease was chosen to demonstrate the technique. TIMS was used to indicate the 
specifical localization of many different lipid species, and of particular interest, 
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ganglioside GM2, asialo-GM2 (GA2) and sulfatides (ST) in Tay-Sachs /Sandhoff mouse 
brain cerebellum. 
After the successful visualization of lipids in brains from Tay-Sachs/Sandhoff 
disease mouse model, in chapter 3, MALDI-TIMS was applied to human ovarian 
carcinoma tissue to detect whether ovarian cancer cells differ in sphingolipid 
composition from neighboring non-cancerous tissue. This study illustrated that ST and 
GalCer are elevated in ovarian cancer by and MALDI TIMS established that STs were 
associated specifically with the regions of the ovarian tissue that bear the carcinoma. 
Gene array data revealed greater expression of mRNAs for GalCer synthase, GalCer 
sulfotransferase (Gal3ST1) and other enzymes of ST biosynthesis in epithelial ovarian 
carcinoma cells.  
Chapter 4 was focused on the subcelluar location of sphingolipids. Using a 
Hek293 cell line stably overexpressing serine palmitoyltransferase (SPT1/2 cells) as a cell 
model, this study explored how impairment of ER/Golgi trafficking would elevate 
C18-Cer and GalCer.  Since Cer is known to inhibit protein ER/Golgi trafficking, this 
study found that the higher production of Cer caused impairment of ER/Golgi trafficking 
of Ceramide synthase 1 (CerS1), thus increased C18-Cer. In addition, since GalCer is only 
synthesized in the lumen of the ER, this impairement of ER/Golgi trafficking also gave 
GalCer synthase access to its substrate and increased GalCer biosynthesis.  
With the development and application of new techniques, one can gain a deeper 
understanding of how sphingolipids are involved in living organisms, and hopefully this 
knowledge will be useful for diagnosis and treatment of the sphingolipids related 






Analysis of lipids in brain from a mouse model of Tay-Sachs/Sandhoff 




2.1 Abstract   
The quality of tissue imaging by matrix assisted laser desorption/ionization mass 
spectrometry (MALDI-MS) depends on the effectiveness of the matrix deposition, 
especially for lipids that may dissolve in the solvent used for the matrix application.  An 
oscillating capillary nebulizer (OCN) was used to spray small droplets of matrix aerosol 
onto the sample surface for improved matrix homogeneity, reduced crystal size, and 
controlled solvent effects.  This system was applied to the analysis of histological slices 
of brains from mice with homozygous disruption of the hexb gene (hexb
-/-
), a model of 
Tay-Sachs and Sandhoff disease, versus the functionally normal heterozygote (hexb
+/-
) by 
imaging MALDI-MS.  This allowed profiling and localization of many different lipid 
species, and of particular interest, ganglioside GM2, asialo-GM2 (GA2) and sulfatides 
(ST).  The presence of these compounds was confirmed by analysis of brain extracts 
using electrospray ionization in conjunction with tandem mass spectrometry (MS/MS).  
The major fatty acid of the ceramide backbone of both GM2 and GA2 was identified as 
stearic acid (18:0) versus nervonic acid (24:1) for ST by both tissue-imaging MS and ESI 
                                                 
1 The content of this chapter has been published ( Chen, Y., Allegood, J., Liu, Y., Wang, E., Cachon-Gonzalez, B., Cox, 
T. M., Merrill, A. H., Jr., and Sullards, M. C. (2008) Anal Chem 80(8), 2780-2788). My major work in this project is 
sample preparation, H&E staining for tissue slide and tissue anatomy explanation. 
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MS/MS.  GM2 and GA2 were highly elevated in hexb
-/-
 and were both localized in the 
granular cell region of the cerebellum.  ST, however, was localized mainly in 
myelinated fiber (white matter) region of the cerebellum as well as in the brain stem with 
a relatively uniform distribution had similar relative signal intensity for both hexb+/- and 
hexb-/- brain.  It was also observed that there were distinct localizations for numerous 
other lipid subclasses, hence, imaging MALDI mass spectrometry could be used for 
“lipidomic” studies.  These results illustrate the usefulness of tissue imaging 
MALDI-MS with matrix deposition by OCN for histological comparison of lipids in 
tissues such as brains from this mouse model of Tay-Sachs and Sandhoff disease.   
2.2 Introduction  
Human Tay-Sachs and Sandhoff disease are a progressing neurodegenerative 
disorders disease and resulted from impaired degradation of GM2 ganglioside and related 
substrates (123, 183). Tay-sachs/Sandhoff diseases are incurable and the molecular 
pathogenesis of brain injury associated with GM2 storage in humans and animals is not 
clear yet (123, 183). To fully understanding the complex pathological processes that 
occur in brain requires not only the elucidation of the biological active molecules 
involved in these processes, but also their spatial distribution within the organism.  
Imaging matrix assisted laser desorption/ionization mass spectrometry (MALDI-MS) 
is a powerful tool that can be used to determine the spatial distribution and relative 
abundance of specific molecules in biological samples such as histological slices of 
tissues (182, 184-186).  In this technique, a MALDI matrix compound is uniformly 
deposited over the surface of a frozen tissue section mounted on a MALDI plate, then a 
pulsed laser is used to desorb and ionize compounds from specific locations (pixels) on 
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the sample surface. The resulting ions can be separated and analyzed by MS to provide a 
full mass spectrum from each location.  By rastering the laser across the sample surface 
in an ordered array, virtual images of the location of selected ions of interest may be 
generated. Thus, imaging MALDI-MS can be used to visualize the distribution and 
relative abundances of large numbers of biomolecules. 
Matrix deposition is one of the factors that critically affects the 
desorption/ionization process and, thus, the quality of MALDI image in terms of mass 
resolution, detection sensitivity, spatial resolution and reproducibility. The oscillating 
capillary nebulizer (OCN) (187, 188) is a low cost device that has been reported to 
provide a uniform matrix coating for accurate mass analysis and provides good sensitivity 
as well as reproducibility (189-191),  but has not yet been used in imaging MS.  Some 
of the advantages of OCN are that it can generate small droplets/aerosols with a narrow 
size distribution(187) by nebulizing the matrix solution at the capillary tip, and it can 
effectively handle liquid compositions from 100% aqueous to 100% organic (191).  By 
controlling the parameters of OCN operation, the solvent content of the droplet 
approaching the sample surface can be optimized (191) to reduce the analyte migration 
and enhance the matrix-analyte interaction. This feature indicates the strong potential of 
OCN to improve the quality of imaging MALDI-MS.  Furthermore, OCN works well 
for both micro-flows (ul/min) and macro-flows (ml/min) with high transport efficiencies 
(192), which can greatly minimize the time for matrix coating. This makes the OCN 
matrix application system very suitable for high throughput sample preparation with 
automation of the sample stage. Therefore, OCN should be a promising sample 
preparation technique to accomplish easy, fast, and high quality imaging mass 
spectrometry analysis of biological molecules. 
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In this paper, we demonstrate the use of an OCN matrix coating system coupled 
with imaging MALDI-MS for the analysis of lipids in tissue slices from normal brain and 
brain from mice mouse model for Tay-Sachs and Sandhoff disease. The mice mouse 
model for Tay-Sachs/ Sandhoff disease allowed visualization of the co-location of the 
two elevated glycosphingolipids, GM2 and asialo-GM2 (GA2), as well as the distinct 
localization of other brain lipids, such as sulfatides, which do not differ noticeably 
between the normal and diseased brain. These results illustrate the usefulness of matrix 
deposition by OCN for histological comparison of even difficult to study compounds 
such as lipids by tissue imaging MALDI-MS. 
 
2.3 Experimental Section 
2.3.1 Chemicals   
The compounds used in this study were from the following commercial sources:  
2,5-dihydroxybenzoic acid (DHB) (Aldrich Chemicals, Milwaukee, WI); trifluoroacetic 
acid (TFA) (Fisher Scientific, Pittsburgh, PA); sulfatides (Porcine Brain) and a total 
ganglioside mixture (Porcine Brain) (Avanti Polar Lipids Inc., Alabaster, AL); and 
monosialogangliosides GM1, GM2 and GM3 (as NH4
+
 salts) (Matreya LLC, Pleasant 
Gap, PA);  Hematoxylin-Eosin (H&E) Staining Solution (VWR, West Chester, PA).  
All solvents were HPLC grade (EMD Chemicals, Gibbstown, NJ) and nanopure water 
(18 MΩ) was used throughout the experiments.   
 
2.3.2 Experimental animals  




 mice (bred from strain: B6;129S-Hexbtm1Rlp, 
Jackson Laboratory, with confirmation of the hexb genotype by PCR) were obtained as 
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described in a previous publication (164).   The studies were conducted using protocols 
approved under license by the U.K. Home Office (Animals Scientific Procedures Act, 
1986).  
 
2.3.3 Tissue sectioning  
The dissected brains were frozen in liquid nitrogen and stored at - 80
 o
C. Before 
tissue section, the frozen brains were first put into a sealed dry-ice box to equilibrate at 
that temperature for 60 min, they were then transferred into the cryostat at - 20
 o
C for 
another 60 min. before sectioning as 10 µm slices at -18 
o
C and thaw-mounted onto 
chilled MALDI plates.  Neighboring sections were also cut under the same conditions 
and thickness, then thaw-mounted onto glass-slides for histological staining.  The tissue 
slices on the MALDI plates were slowly brought to room temperature in a desiccator 
before matrix coating.  
 
2.3.4 Histological staining  
Tissue sections on glass slides were stained using routine protocol of H&E staining 
for frozen sections on a Leica autostainer XL (Leica Microsystems, Bannockburn, IL).  
The histological images were taken with a Nikon Eclipse E600 microscope (Nikon, 
Melville, NY). 
 
2.3.5 Optimized TLC sprayer conditions  
The TLC conditions were optimized according to a previously published report.(193)  
A 25-mL TLC reagent sprayer with standard ground glass joint (Kimble/Kontes, 
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Vineland, New Jersey USA) was used to spray matrix solution (30 mg/mL DHB in 50:50, 
v:v, acetonitrile:water with 0.1% TFA) onto the brain tissue.  The operating pressure of 
nitrogen was ~7 psi. The distance between the nozzle and the sample was ~12 cm.  
Multiple matrix coating cycles with discrete spraying and drying were performed to get 
better imaging results.  Typically, the spraying and drying time for a 10  10 mm 
sample was 10 and 30 seconds, respectively.  Usually 30 coating cycles were required 
for the brain tissues to provide an optimal matrix thickness of 5 ~ 50 µm.  The average 
crystal size of DHB matrix using this protocol was ~ 100 µm. 
 
2.3.6 OCN Matrix application system   
A diagram of the design and operation of the oscillating capillary nebulizer (OCN) 
matrix application system is shown in publication (194).  The matrix solution (30 
mg/mL DHB in 50:50, v:v, acetonitrile:water with 0.1% TFA) was delivered to the OCN 
sprayer using a syringe pump (KD Scientific, Holliston, MA) at a flow rate of ~ 60 
µl/min.  The OCN sprayer (187) consists of two coaxial fused silica capillary tubes 
(Polymicro Technologies, LLC, Phoenix, AZ) that are friction-fit mounted with PEEK 
Sleeves (Upchurch Scientific, Oak Harbor, WA) housed in a 1/16’’ stainless steel union 
tee (Swagelok, Solon, OH).  The inner capillary (i.d. 50 µm, o.d 150 µm, length 80 mm) 
was used to transfer the matrix solution and the outer capillary (i.d. 250 µm, o.d. 350 µm, 
length 30 mm) allowed nitrogen (~50 psi) to pass through the annular space between the 
outer wall of inner capillary and inner wall of the outer capillary to generate the 
oscillation of the inner capillary tip, which extends about 1 mm (R) from the outer 
capillary tip.  The high frequency oscillation induces the nebulization of the matrix 
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solution and generates a fine and uniformly dispersed spray of matrix droplets/particles. 
The typical distance (L) between the OCN and the sample on the xyz translation stage 
(Newport, Irvine, CA) is ~10 cm depending on the flow rate of the matrix solution and 
gas pressure.  The sample was continually moved across the aerosol deposition area in 
the X direction (5 mm/s) and Y direction (5 mm/s) to obtain an even matrix distribution 
throughout the sample surface.  The typical time of matrix coating for a 4 cm
2 
sample is 
about 5 min with an estimated thickness of 10-20 µm. 
 
2.3.7 Imaging MALDI-MS   
MALDI mass spectra were acquired using a Voyager DE STR MALDI-TOF-MS 
(Applied Biosystems) with a 337 nm N2 laser (3 Hz, ~ 100 µm) under delayed extraction 
conditions in reflector mode. The accelerating voltage, grid voltage and delay time were 
22kV, 70% and 400 ns, respectively.  The mass spectrometer was calibrated using 
sulfatides (Porcine Brain) and a total ganglioside mixture (Porcine Brain).  Imaging 
MALDI mass spectrometry data sets were acquired using modified MMSIT (without 32k 
data limitation) over the tissue section. In this work, nine shots were summed on each 
sample spot and the step size of sample stage was 60 µm.  Ion images were reconstituted 




   
GM2, GA2 and sulfatide were analyzed by ESI-MS/MS, and ESI-MS
3
 to confirm 
both their identities and determine their structures.  Briefly, the tissues were 
homogenized (10 mg/ml) in 10 mM potassium phosphate buffer (pH 7.4) on ice, 
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extracted  and the acidic glycolipids recovered by batch elution from a DEAE-column 
(195). The final extracts were dissolved in 1.0 ml of MeOH and introduced via syringe 
infusion (0.6 mL/h) into an API 4000 QTrap tandem mass spectrometer. Acidic 
gangliosides and sulfatides were examined in negative ion mode, while neutral 
glycosphingolipids were examined in positive ion mode. 
Sulfatides fragment via cleavage and charge retention by their sulfate to yield a 
primary product ion of m/z 96.9.  Precursor ion scans for m/z 96.9 were used to 
determine the potential N-acyl chain length subspecies in each sample.  These scans 
were performed with declustering potential (DP) of -220 eV and collision energies 
ranging from -100-120 eV. Once individual sulfatide subspecies were identified, 
ionization conditions were optimized for each and enhanced product ion (EPI) scans were 
performed to structurally identify the sulfatide species because it revealed a greater 
diversity of product ions than Q3 scans.  EPI scans were performed with Q0 trapping set 
to “on”, a linear ion trap fill time of 100 ms, and a scan rate of 1000 amu/s.   
Acidic gangliosides fragment primarily via cleavage of their sialic acids (m/z 290.1) 
and other glycans.  Precursor ion scans for m/z 290.1 were used to identify the potential 
N-acyl chain length subspecies within each family of acidic gangliosides (i.e. GM1, GD1, 
GT1).  These scans were performed with declustering potential of -70-100 eV (lower 
DP was required to reduce in-source fragmentation for species having multiple sialic acid 
residues).  Collision energies ranged from -55-75 eV with lower collision energies used 
for species having increasing numbers of sialic acid residues because of the liability of 
these molecules toward fragmentation.  Once individual ganglioside subspecies were 
identified, ionization conditions were optimized for each and EPI scans were performed 
with Q0 trapping set to “on”, a linear ion trap fill time of 100 ms, and a scan rate of 1000 
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amu/s.  An MS
3
 analysis is performed in much the same manner as a product ion scan.  
In this case the first mass analyzer (Q1) is set to “open” to pass a wide m/z window (6-10 
amu) around the precursor ion of interest, which is transmitted to Q2 where it collides 
with a neutral gas (N2) and dissociates to various fragment ions. Rather than mass 
analyzing the resulting product ions, the linear ion trap (LIT) is set to trap and hold a 2 
m/z unit window centered on the product ion of interest. The selected m/z ions are then 
irradiated with a single wavelength, amplitude frequency to induce further fragmentation 
to secondary product ions, which are then scanned out of the LIT.  The sphingoid base 




Neutral glycosphingolipids were analyzed in positive ion mode as both (M+H)
+
 and 
(M+Na)+ species.  Neutral glycosphingolipids fragment primarily via cleavage of 
carbohydrate groups.  Potential subspecies were identified via neutral loss scans for 
hexose and N-acetyl-hexosamine (162 u and 203 u respectively).  The parameters of EPI 
and MS
3
 scans for neutral glycosphingolipids were kept the same as those for acidic 
gangliosides. 
 
2.4 Results and Discussions 
2.4.1 Examination of mouse brain sphingolipids using the OCN for matrix deposition. 
Mouse brain tissue (hexb+/-) samples having matrix deposition by a TLC sprayer 
was compared to those prepared with the OCN system.  The resulting MALDI-MS data 
revealed the formation of an ion of m/z 888.9 in both samples.  This ion is subsequently 
shown to be a sulfatide (galactosylceramide-3-O-sulfate with the d18:1/C24:1 backbone), 
consistent with previous reports (196).  The MALDI-MS image of this ion in the TLC 
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prepared sample (Fig. 2.1 lower left) followed the general contour of the tissue (Fig. 2.1 
upper left).  However, there were no features in the image that could be unambiguously 
correlated with specific regions of the brain.  In contrast, the MALDI-MS image of m/z 
888.9 in the tissue slice with matrix deposition via the OCN (Fig. 2.1 lower right) showed 
a good correlation with the H&E stained histological image (Fig. 2.1 upper right) with 
regard not only to sample shape but also to the fine tissue structures.  The myelinated 
fiber (white matter) regions in the cerebellum were all successfully illustrated by the ion 
image.  The imaging differences between the two matrix coating techniques were highly 
reproducible as evidenced by multiple experiments.  
These images clearly demonstrate the OCN system is useful for sample preparation 
for MALDI-MS imaging of lipids.  An important feature of the OCN system is the 
ability to minimize the amount of solvent that comes into contact with the tissue.  This 
serves to reduce analyte migration and matrix crystal size to minimize the loss of 
molecular spatial information.  Further applications of the OCN coating system may 
include computer control providing more precise and reproducible matrix deposition.  
Additionally, this may allow multiple samples to be prepared in an unattended fashion for 
high-throughput sample preparation under optimal conditions.  
 
2.4.2 Additional features noted upon MALDI-MS imaging of sphingolipid subspecies 
in mouse brain.  
MALDI-MS spectra acquired in the negative mode for the hexb (-/-) mouse brain slices 




Fig. 2.1.  Representative images obtained by matrix applications using a TLC 
sprayer and an OCN sprayer. The fine structures (molecular layer, myelinated fiber, 
and granular layer) of hexb
+/-
 mouse brain (cerebellum) are labeled in the upper H&E 
stained images.  Negative ion mode MALDI images of m/z 888.9 found in mouse brain 
tissues together with MALDI mass spectra generated from specific brain spots are shown 





1383 (Fig 2.2a and b) localized in different regions of the brain.  The image generated 
from the spatial distribution of the m/z 888.9 ion (d18:1/C24:1 sulfatide) displayed a 
remarkably similar pattern to the myelinated fiber (white matter) region of the cerebellum 
and a relatively even distribution in brain stem (c.f., H&E staining) (Fig. 2.2a).  The 
image generated from the m/z 1383 ion (d18:1/C18:0 ganglioside GM2) most closely 
matched the granular cell region in cerebellum and produced no detectable ions in the 
brain stem region (Fig. 2.2b).   
In positive mode, a number of intense ions were seen in the range of m/z 700-1400 
(Fig. 2.3).  Of particular interest are m/z 772.6 and 1132, which have significantly 
different localizations from each other. The ion of m/z 772.6 is found primarily in the 
molecular layer region and the ion of m/z 1132 is found mainly in the granular cell 
region.   
Furthermore, it is also observed that there is a remarkable similarity in the 
localization of m/z 1132 (Fig. 2.3 upper right) and m/z 1383 (Fig. 2.2b).   This is 
interesting because m/z 1132 corresponds to the mass of potassiated asialo-GM2 
(d18:1/C18:0), which is also known to accumulate in mice with this genetic defect (196), 
but to our knowledge, this is the first study to visualize their co-localization. 
Neither GM2 nor GA2 were detected in hexb
+/-
 brains but they were highly 
elevated in hexb
-/- 
brains.  This was in contrast to ST, which had similar signal 
intensities in both hexb+/- and hexb-/- brains (similar observations were also seen in the 
ESI MS/MS spectra for the brain extracts, data not shown).  In addition, GM2 and GA2 
were observed to be co-localized in the granular layer region of cerebellum (Fig. 2.2 and 




Fig. 2.2. Imaging MALDI-MS data from hexb (-/-) mouse brain (cerebellum, 7.164 x 
3.729 mm) using negative ion mode. The fine structures of cerebellum in the H&E 
stained images are labeled as: 1) molecular layer, 2) myelinated fiber (white matter), and 
3) granular layer.  The MALDI spectra present the ion yield from specific spots in (a) 
myelinated fiber (white matter), and (b) granular layer region, respectively.  The 


































Fig. 2.3. Imaging MALDI-MS data from hexb (-/-) mouse brain (cerebellum, 7.164 x 
3.729 mm) using positive ion mode. The MALDI spectrum presents the ion yield from a 
spot at the boundary of molecular layer and granular layer regions.  The molecular 
distributions of m/z 772.6 and m/z 1132 are compared with the H&E stained image. 
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 cerebellum and the brain stem with a relatively uniform distribution (Fig. 2.1 and 2.2). 
 
2.4.3 Confirmation of the identity and structure of GM2 and sulfatide by MS
n
.   
Analysis of the lipid extracts from the mouse brains was performed to confirm the 
presence of sulfatide, GM2, and GA2 (spectra not shown).  In negative ion mode, 
MS/MS of m/z 1382.9 generates five major fragment ions corresponding to losses of 
different sugar moieties in the head group (Fig. 2.4a).  The product ions of m/z 1091.8, 
888.7, 726.6 and 564.6 correspond to the Y-type glycosidic bond cleavage involving loss 
of NeuAc, NeuAc/GalNac, NeuAc/GalNac/Gal, and NeuAc/GalNac/Gal/Glc, 
respectively.  The m/z 290.1 ions were produced by C-type cleavage and charge 
retention on the sialic acid with subsequent dehydration, which confirms the existence of 
a sialic acid moiety.  An MS3 experiment was performed on the Y0 fragment ion of m/z 
564.6 to establish the nature of the ceramide backbone of the m/z 1382.9 ion.  The 
resulting MS
3
 spectra (Fig. 2.4b) showed secondary fragment ions of m/z 324, 308, 282, 
and 283, corresponding to S, T, U, and V + 16 fragments respectively,(178) revealing 
that the amide-linked fatty acid is stearate (C18:0).  The ions of m/z 237 and 263 
correspond to complimentary P and Q fragments respectively (178), showing that the 
sphingoid base backbone is d18:1.  Thus, this major species in hexb (-/-) mouse brain is 
ganglioside GM2 (d18:1/C18:0).  
MS/MS of m/z 888.9 in the negative ion mode (Fig. 2.5) revealed a highly abundant 
fragment ion at m/z 96.8 corresponding to a sulfate group (HSO4); Lower abundance 





Fig. 2.4. (a) ESI-MS/MS spectrum of m/z 1383 and (b) ESI-MS
3
 spectrum of 


























Fig. 2.5. ESI-MS/MS of m/z 888.9
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the sphingoid base with charge retention on the sulfated carbohydrate.  The ion of m/z 
390.2 corresponds to a “T” type cleavage of  both of the sphingoid base and the sugar 
head group with charge retention on the fatty acid, which is identified as nervonic acid 
(C24:1).  Therefore, m/z 888.9 can be identified as a sulfatide 
(galactosylceramide-3-O-sulfate) with a d18:1/C24:1 backbone configuration.  
 
2.4.4 Examples of lipids with distinct spatial distributions.    
Several other prominent ions were distinctly visible in brain samples prepared using 
OCN for matrix deposition (Fig. 2.6).  Although they have not been all independently 
identified structurally via MS/MS, their nominal m/z values are consistent with 
previously published work (197, 198). The ions of m/z 728.6 (plasmenylethanolamine, 
PlsEtn, with C36:1*) were relatively evenly distributed throughout the cerebellum (Fig. 
2.6a), whereas m/z 798.4 (phosphatidylcholine, PC, with C34:1* + K) was predominantly 
observed in myelinated fiber (white matter) and molecular layer regions (Fig. 2.6b).  PC 
with C36:1* + K (m/z 826.5) (Fig. 2.6c) was more specifically localized in myelinated 
fiber (white matter) regions, as were sulfatides, ST, with the d18:1/C24:1 and 
d18:1/C24:0 backbones (m/z 888.9 and 890.8, respectively), and hydroxylated sulfatide, 
ST(OH), with d18:1/h22:0 and d18:1/h24:1 ceramide backbones (m/z 878.8 and 906.8, 
respectively) (Fig. 2.6d-g).  In contrast, the ions of m/z 834.5 (phosphatidylserine, PS, 
with C40:6*), m/z 885.6 (phosphatidylinositol, PI, with C38:4*), and m/z 772.6 (PC with 
C32:0* + K) were highly localized in molecular layer region (Fig. 2.6h-j, respectively), 
while the ion of bcategories of lipids are localized to specific regions of the brain.  
Therefore, this technology is a valuable complement to other types of “Lipidomic” 





Fig. 2.6. Selected ion images of various species from hexb (-/-) mouse brain, which 
illustrate different histological localizations.  a) m/z 728.6 [PlsEtn 36:1*];  b) m/z 
798.4 [PC 34:1*+ K];  c) m/z 826.5 [PC 36:1* + K]; d) m/z 878.8 [ST(OH) d18:1/h22:0]; 
e) m/z 888.9 [ST d18:1/C24:1]; f) m/z 890.8 [ST d18:1/C24:0]; g) m/z 906.8 [ST(OH) 
d18:1/h24:1]; h) m/z 834.5 [PS 40:6*]; i) m/z 885.6 [PI 38:4*]; j) m/z 772.6 [PC 32:0* + 
K]; k) m/z 1383 [GM2 d18:1/C18:0]  * Tentative assignment.(198, 199) PC: 








This study has shown that an oscillating capillary nebulizer (OCN) can be used to 
generate good matrix homogeneity and spatial resolution for visualization of several 
types of lipids including sulfatides, gangliosides and phosphoglycerolipids.   
Its successful usefulness has been indicated here for the visualization of lipids in 
brains from Tay-Sachs/Sandhoff disease mouse model, and it is very likely to have broad 





Elevation of sulfatides in ovarian cancer: An integrated genomic and 
lipidomic analysis including tissue-imaging mass spectrometry 
 
3.1 Abstract 
Sulfatides (ST) are a category of sulfated galactosylceramides (GalCer) that are elevated 
in many types of cancer including, possibly, ovarian cancer.  Analysis of 12 ovarian 
tissues graded as histologically normal or having epithelial ovarian tumors by liquid 
chromatography-electrospray ionization tandem mass spectrometry established that most 
tumor-bearing tissues have higher amounts of ST, and some have elevated GalCer, or both.  
Because ovarian cancer tissues are comprised of many different cell types, histologic tissue 
slices were analyzed by matrix-assisted laser desorption/ionization tissue-imaging mass 
spectrometry (MALDI-TIMS) to identify regions where ST are found relative to those 
identified as ovarian epithelial carcinoma by H & E staining and histological scoring.  
These were in excellent agreement.  Furthermore, the structures for the most prevalent 
species observed via MALDI-TIMS (d18:1/C16:0-, d18:1/C24:1- and d18:1/C24:0-ST) 
were confirmed by tandem mass spectrometry, whereas, a neighboring ion (m/z 885.6) that 
was not tumor specific was identified as a phosphatidylinositol.  Microarray analysis of 
mRNAs collected using laser capture microdissection revealed that expression of GalCer 
synthase and Gal3ST1 (3'-phosphoadenosine-5'-phosphosulfate:GalCer sulfotransferase) 
were approximately 5- and 2-fold higher, respectively, in the ovarian epithelial carcinoma 
cells versus normal surface ovarian epithelial cells (12 each), which is a likely explanation 
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for the increases in GalCer and ST.  In addition to these findings with ovarian tumors, ST 
with very-long-chain-Cer were higher in serum from patients with ovarian cancer.   This 
study combined genomic and lipidomic approaches to establish that the GalCer/ST branch 
of sphingolipid biosynthesis is elevated in ovarian cancer. 
 
3.2 Introduction 
Epithelial ovarian cancer is the fourth leading cause of death for women in the 
United States and has the highest death rate of all gynecological cancer (200). The 5-year 
survival rate is less than 30% (201), in part because accurate diagnosis is often not made 
until it has progressed into more advanced stages. Therefore, knowledge about the 
molecular changes in ovarian cancer cells might aid both the understanding of the 
malignant carcinoma progression and the development of strategies for early detection 
and treatment.  
Glycosphingolipids have long been known to be abnormal in many types of cancer 
(202, 203). One of the categories of glycosphingolipids, sulfatides (ST), have been 
correlated with poor prognosis in colorectal (173) carcinoma, and found in numerous 
other types of cancer, including hepatocellular (204), renal (205), and small-cell lung 
cancers (206).  ST have been suggested to increase in ovarian cancer and possibly to be 
an early predictor of the disease (207).  However, the evidence for elevation of ST in 
ovarian cancer (207) was based on a colorimetric assay (208) that also reacts with 
cardiolipin, phosphatidylserine, phosphatidylinositol and a number of other phospholipids.  
Thus, in this study, we utilized liquid chromatography, electrospray-ionization tandem 
mass spectrometry (LC ESI-MS/MS), which is both structurally specific and quantitative 
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(11), to compare the types and amounts of ST and galactosylceramides (GalCer) (its 
biosynthetic precursor) in ovarian epithelial carcinoma tissue relative to normal ovarian 
samples.  Finding ST to be higher in most of the ovarian cancer samples, the 
histological localization of ST with ovarian epithelial carcinoma cells was established 
using matrix-assisted laser desorption/ionization tissue imaging mass spectrometry 
(MALDI IMS).  Furthermore, to understand the cause(s) for these changes in 
glycosphingolipid composition, the relative expression levels of the mRNAs for the 
biosynthetic pathway for ST biosynthesis were compared for ovarian epithelial carcinoma 
tissue relative to normal ovarian epithelial cells.  This integrated genomic and 
metabolomic approach established that ST levels are abnormal in ovarian epithelial 
cancer cells with changes initiated at the level of expression of genes for ST biosynthesis.  
 
3.3 Materials and Methods 
3.3.1 Tissue collection 
For the mass spectrometric analyses (LC ESI-MS/MS and MALDI TIMS), 12 
serous papillary ovarian cancer tissues from women with a mean age of 59 years (range 
46–71, categorized as stages IIa–IV ovarian cancer) and 12 histologically normal tissues 
(from women with a mean age of 54 years, range 36–84) were collected during surgery, 
sealed in cryotubes and frozen in liquid nitrogen in less than one minute.  For the 
analysis of serum ST by LC ESI-MS/MS, blood from 12 patients with serous papillary 
ovarian cancer (mean age 60 years, range 49–71, stages Ic–IV) and 12 controls (mean age 
54 years, range 41–78) was drawn into BD Vacutainer® serum collecting tubes (BD, 
Franklin Lakes, New Jersey), then serum was collected and transferred into eppendorf 
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tubes (200 µl serum/tube) and frozen in liquid nitrogen in less than one minute.  For the 
gene expression analysis, serous papillary ovarian cancer samples from 12 patients with a 
mean age of 59 years (range 48–71, stages Ic–IV) were collected during surgery, sealed 
in cryotubes and frozen in liquid nitrogen in less than one minute; healthy ovarian surface 
epithelial cells were collected from 12 patients (mean age of 53 years, range 41–78) at the 
time of surgery using a pap brush and stored in RNAlater solution (Ambion, Austin, TX) 
at –20
o
C. Normals were defined as patients at Northside Hospital with ovarian histology 
considered within normal limits, WNL, and women with non-cancerous ovarian 
conditions.  All of the samples were collected at Northside Hospital (Atlanta, GA) and 
later transported to Georgia Institute of Technology on dry ice, and stored at –80
o
C for 
future use.  All of the work in this project followed Georgia Institute of Technology and 
Northside Hospital IRB approved protocols. 
 
3.3.2 Sphingolipid analysis by LC ESI-MS/MS 
The tissues (typically in the range of 0.7 to 1.6 mg) were prepared as 10% 
homogenates (w/v, in distilled, deionized water) and the serum (12.5 µl) were extracted 
for analysis of GalCer and ST by mass spectrometry as previously described (177, 178).  
After addition of the solvents to the tissue homogenate, an internal standard cocktail 
consisting of 25 pmol of C12-ST and C12-glucosylceramide (GlcCer) (Avanti Polar 
Lipids, Alabaster, AL) was added.  The LC ESI-MS/MS analysis was conducted using a 
Perkin Elmer Series 200 autoinjector, and a Shimadzu LC-10 AD VP binary pump 
system coupled to a 4000 quadrupole linear-ion trap (QTrap) (Applied Biosystems, 
Foster City, CA).   
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For GalCer analysis, the lower phase organic extract was resuspended in 300 µl of 
mobile phase, representing about 1 mg of original tissue, then 30 µl were analyzed by LC 
ESI-MS/MS using a Supelco 2.1 mm x 25 cm SUPELCOSIL LC-Si column (Sigma, St. 







COOH (97:2:1, v:v:v) with 5 mM ammonium acetate.  For every 
run, the column was equilibrated for 1.5 min prior to injection, the sample was injected 
and eluted for 8 min (with GlcCer, and GalCer eluting at ~ 3 min and 3.5 min, 
respectively, with baseline resolution), followed by re-equilibration of the column for the 
next run. Resolution of these isomers was confirmed during the analysis by interspersing 
vials with internal standards (C12GalCer and C12GlcCer) throughout the runs. 
For ST analysis, the extract was resuspended in 300 µl of LC solvent (CH3OH:H2O, 
95:5, v:v, with 5 mM ammonium acetate and 0.01% NH4OH), representing about 1 mg of 
original tissue, then 50 µl was analyzed by reverse-phase LC ESI-MS/MS using a 2.1 x 
20 mm Ace C18 column (MAC-MOD Analytical, Chadds Ford, PA) eluted at flow rate 
of 0.5 mL/min. The column was first equilibrated with a 10:90 (v:v) mixture of mobile 
phase solvent A (CH3OH:H2O, 50:50, v:v, with 5 mM ammonium acetate and 0.01% 
NH4OH) and solvent B (CH3OH with 5 mM ammonium acetate and 0.01% NH4OH) for 
2 min, then sample was injected and eluted with this mixture for 1 min, followed by a 
gradient to 100% solvent B over 3 min, then sustained at 100% solvent B for 5 min, 
during which the different subspecies of ST elute (between ~ 4 and 7 min); finally, the 
solvent was restored to the original A:B mixture (10:90, v:v) by a 1 min gradient, and 
equilibrated for 2 min before the next run. 
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The declustering potential (DP) and entrance potential (EP) for the API 4000 QTrap 
were adjusted to achieve the optimal ionization conditions. After the Q1 settings were 
determined, product ion spectra were collected across a range of collision energies (CE), 
structurally specific product ions were identified, and collision energies and collision cell 
exit potentials (CXP) were manipulated to produce optimal signal. For GalCer, DP was 
35.0 V, EP was 10.0 V, CXP was 15 V, CE was from 50 to 70 V. For ST, DP was -220.0 
V, EP was -10.0 V, CXP was -14.0 V, CE was from -55 to -130 V.  
The lipid extracts were initially examined for GalCer species by a precursor ion scan 
of m/z 264.4 in positive ionization mode, and for ST by a precursor ion scan for 
precursors for m/z 96.9, which is specific for the HSO4 moiety in negative ionization 
mode. The resulting precursor/product pairs were used for quantitative analysis by 
multiple reaction monitoring (MRM) (15). This preliminary analysis found that the only 
detectable subspecies were the sulfated monohexosylceramide HSO3-3Galβ-1Cer and 
GalCer with the Cer backbones listed below. Using this information, Q1 and Q3 were set 
to cycle through these precursor and product ions pairs with a dwell time of 25 ms for 
each GalCer transition and 20 ms for each ST transition and an interchannel delay of 5 
ms between transitions. For GalCer, the transitions occur at m/z with the nature of the 
lipid backbone of the sphingolipid in parentheses (sphingoid base carbon number:number 
of double bonds/fatty acid carbon number:number of double bonds): 700.7/264.4 
(d18:1/16:0), 728.7/264.4 (d18:1/18:0), 756.7/264.4 (d18:1/20:0), 784.8/ 264.4 
(d18:1/22:0), 810.9/264.4 (d18:1/24:1), 812.9/264.4 (d18:1/24:0), 838.9/264.4 
(d18:1/26:1), and 840.9/264.4 (d18:1/26:0); for ST, the transitions occur at the following 
m/z 778.6/96.9 (d18:1/16:0), 806.6/96.9 (d18:1/18:0), 834.5/96.9 (d18:1/20:0), 862.6/96.9 
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(d18:1/22:0), 888.6/96.9 (d18:1/24:1), 890.6/96.9 (d18:1/24:0), 916.6/96.9 (d18:1/26:1), 
and 918.6/96.9 (d18:1/26:0). The quantity of each subspecies was determined by 
comparison of the areas for each MRM transition with the areas of the spiked internal 
standards as previously described (177) (178). Tissue extracts were normalized by the 
protein amount in the tissue homogenate using the BCA method (Thermo Sci, Rockford, 
IL). 
 
3.3.3 MALDI tissue-imaging mass spectrometry  
The tissue distribution of ST was determined essentially as described by others (209, 
210), with recent modifications (194, 211). Starting with ovarian tissues that had been 
frozen in liquid nitrogen and stored at - 80oC, the frozen tissue was put into a sealed 
dry-ice box for 60 min, mounted in a LEICA CM3050S cryostat (LEICA, Germany) at - 
20
o
C for ~30 min, then sectioned into 10 µm thick slices (avoiding folding) and 





C until analysis (within a month). Neighboring 10-µm slices were 
thaw-mounted into glass slides for hematoxylin-eosin (H&E) staining.  To analyze the 
tissue slices by TIMS, the tissue slices on the MALDI plate were slowly brought to room 
temperature in a desiccator before a matrix solution (2-mercaptobenzothiazole, from 
Sigma, at 5 mg/mL in methanol) (211) was sprayed onto the sample using an oscillating 
capillary nebulizer sprayer (OCN) with a syringe pump (Harvard, Canada) as described 
previously (194). The typical time required for matrix coating of a 4 cm
2 




Mass spectra for imaging were acquired using a Voyager DE STR MALDI-TOF 
mass spectrometer (Applied Biosystems, Foster City, CA) with a 337 nm N2 laser (3 Hz) 
under delayed extraction conditions in reflector mode. The accelerating voltage, grid 
voltage, and delay time were 20 kV, 72% and 220 ns, respectively.  MALDI TIMS data 
sets were acquired using modified MMSIT (MALDI MS Image Tool) (Applied 
Biosystems) (without 32k data limitation) over the tissue section. Twelve laser shots were 
summed for each sample spot and the step size of sample stage was 60 µm. Ion images 
were reconstituted using BioMap software package (Novartis Pharma AG, Basel, 
Sweden).  
For comparison of the ion intensities of sulfatides in different regions of the tissue 
slice, sample spots (60 µm) were chosen as described in the text.  The ion intensity for 
the m/z of interest is analyzed by one-tailed Wilcoxon rank sum test with P<0.05 
considered to be significantly different. 
The major ions of interest (i.e., putative ST) underwent further structural analysis 
using a hybrid quadrupole time-of-flight mass spectrometer (Q-STAR, Applied 
Biosystems Foster City, CA) equipped with an O-MALDI source using a 337 nm N2 
Laser (30 Hz).  The laser energy and instrument parameters were optimized for MS/MS 
analysis of the fragmentation of the precursor ion to informative product ions.  Briefly, 
the DP was 0.0, Focusing Potential (FP) was -80.0, DP2 was -15.0 , CE was varied from 
-20 to -80 V, Collision Gas (CAD) was 6, Ion Energy 1(IE1) was -0.9, DC Quad Lens 
Horizontal Focus (GR) was -5.0, and laser relative intensity was 22%. 
 
3.3.4 RNA isolation, amplification and microarray analysis 
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For analysis of gene expression in the ovarian cancer cells, the frozen tisues were 
embedded in cryomatrix (Shandon, Thermo Fisher scientific, Waltham, MA) and 
sectioned into 7-µm thick frozen slices using a cryostat and were subsequently attached 
to uncharged microscope slides. Immediately following dehydration and staining 
(HistoGene LCM Frozen Section Staining Kit, Arcturus, Molecular Devices, Sunnyvale, 
CA), slides were placed in an AutoPix™ LCM instrument (Arcturus) for laser capture 
microdissection (LCM) of cells to CapSure Macro LCM Caps Arcturus).  Approximately 
30,000 epithelial cells were collected from each of the twelve cancer samples, then RNA 
was extracted in 25 µL of extraction buffer using the PicoPure RNA Isolation Kit 
(Arcturus).  RNA was isolated from the normal surface ovarian epitheial cells stored in 
RNAlater solution using the RNAlater kit (Ambion, Foster City, CA).  Biotin labeled 
mRNA was prepared from the previously isolated mRNA from tumor and normal cells 
using the RiboAmp OA or HS kit (Arcturus) in conjunction with the IVT Labeling Kit 
(Affymetrix, Santa Clara, CA) for hybridization to Human Genome U133 Plus 2.0 Array 
GeneChips (Affymetrix) for 3' expression analysis. The arrays were processed following 
the GeneChip→ Expression Technical Manual to generate feature level expression results 
(.CEL files).  The .CEL files were processed to generate a probe set summarization file 
by the Affymetrix Expression Console (EC) Software Version 1.1 software, which uses 
the default MAS5 3’ expression workflow which scaled all probe sets to a target intensity 
(TGT) of 500.  AFFX-BioB, AFFX-BioC, AFFX-BioDn, and AFFX-CreX were used as 




3.3.5 Analysis and visualization of the gene expression data using a GenMapp pathway 
diagram for sphingolipids 
The expression levels for the genes of interest were extracted from the probe set 
summarization file. The average fold difference for each gene was calculated for the 12 
samples each of normal ovarian surface epithelia versus the serous papillary ovarian 
cancer epithelia using a per script (ActivePerl v5.8, ActiveState, Vancouver, BC). The 
results were visualized using GenMapp v2.1 (212), a program for the creation and 
visualization of gene expression data related to a specific biochemical or signaling 
pathway in a KEGG pathway pattern (213), as recently modified for sphingolipids (2).  
The fold-differences were visualized by the color criteria shown in the figure. 
 
3.3.6 Statistical analysis   
The statistical analysis was performed using software R 2.8.1 (R-project.org). Data 
were analyzed using one-tailed Wilcoxon rank sum test. The results were considered 
statistically significant if P<0.05.  
 
3.4 Results 
3.4.1 Cellular amounts of ST and GalCer in human normal ovarian tissue and serous 
papillary ovarian carcinoma tissue 
Shown in Figure 1B and C are the amounts of GalCer and ST found in 12 normal 
ovarian tissue and 12 serous papillary ovarian carcinoma tissues analyzed by LC 
ESI-MS/MS.  GalCer was 3-fold higher for the cancer tissue than for the normal tissue 
with mean ± SE of 9.4 ± 3.7 versus 2.7 ± 0.6 pmol GalCer/mg protein, respectively (Fig 
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3.1B) (P =0.13, n=12 for each group by one-tailed Wilcoxon rank sum test).  ST was 
8-fold higher for cancer tissue than normal (39.8 ± 13.9 versus 5.2 ± 2.1 pmol ST/mg 
protein, respectively, P=0.006, n=12 for each) (Fig 3.1C).  
 
3.4.2 Identification of ST in serous papillary ovarian carcinoma tissues by MALDI 
tissue-imaging mass spectrometry (MALDI TIMS) 
Ovarian cancer tissue is comprised of a number of cell types, including the ovarian 
epithelial carcinoma and non-malignant stroma tissue, therefore, MALDI TIMS was used 
to examine in which areas the increased ST are found (reanalysis of GalCer was not 
conducted because MALDI TIMS cannot distinguish isobaric GalCer and 
glucosylceramide, GlcCer). Fig 3.2A shows a typical H&E stain of a thin section of 
ovarian carcinoma tissue showing regions of well differentiated serous papillary 
carcinoma with fibrovascular structure lined by micropapillary epithelium with cytologic 
atypia, loss of nuclear polarity and mitotic figure. Serous papillary carcinoma cells are 
replacing the ovary and apparently present on the ovarian surface with stromal invasion. 
A typical fibrovascular stroma is labeled “a” and representative malignant epithelial cells 
are labeled “b”.  There are a few spaces with no visible cells, labeled ”*”.  MALDI 
TIMS analysis of representative malignant epithelial cells gave spectra similar to that in 
panel B (the spectrum for the specific spot shown), with readily seen ions with m/z 778.6, 
885.6, 888.6 and (in greater amounts in samples than the one shown) 890.6, which 
correspond to ST with the backbones d18:1/C16:0, an unknown species, d18:0/C24:1, 
and d18:1/C24:0, respectively.  In contrast, spectra from the stromal region (one 




Fig 3.1. Elevation of sulfatides (ST) and galactosylceramides (GalCer) in ovarian 
carcinoma versus normal tissue  These sphingolipids were extracted from 12 ovarian 
tissues scored as histological normal or as ovarian cancer (serous papillary epithelial 
carcinoma from stage IIa to stage IV) then analyzed by liquid chromatography 
electrospray ionization tandem mass spectrometry as described in the text and reference 
(177).  Shown are the means for triplicate analysis of each sample, with analytical SD of 
10 to 20% of the mean for each sample (not shown).  Panel A shows the biosynthetic 
pathway from Cer to ST; and panels B and C display the Means ± SE for GalCer and ST, 













Fig 3.2. A representative analysis of a histological thin section from an ovarian 
carcinoma sample by MALDI tissue imaging mass spectrometry (MALDI TIMS). 
Panel A shows a thin section (10 µm) with the usual H & E staining; panels B and C are 
examples of spectra obtained from the shown regions of the adjacent thin section (10 µm) 
that has been deposited on a MALDI plate, impregnated with MALDI matrix material, 
then irradiated with a N2-laser to generate ions in spots of an approximately 60 µm in 
diameter (which are the approximate dimensions of the spots shown) and analyzed in 
negative ion mode using a Voyager DE STR MALDI-TOF mass spectrometer.  The 
black spots were histologically scored as serous papillary epithelial carcinoma; the blue 
spots were scored as non-malignant stromal cells.  Panel D shows the ion intensities of 
the m/z 778.6 (d18:1/C16:0 ST) species from regions scored as normal (n=20) or ovarian 
cancer (n=23). (columns, mean for ion intensity of the m/z 778.6; bars, SE). P value was 







 shows a distribution diagram for the intensities of the m/z 778.6 (d18:1/C16:0 ST) for all 
of the randomly selected spots shown in Panel A with blue for the histologically normal 
stromal (n=23) versus black for carcinoma regions (n = 20).  The mean intensity of m/z 
778.6 in the carcinoma region was 556 ± 99 versus 178 ± 57 in the stroma area 
(P=0.00003).   
  
3.4.3 Structural analysis by MALDI tissue-imaging MS/MS 
Structural assignments based on MS data alone have the possibility of being in error 
if the sample happens to contain another compound with the same m/z as the compound 
of interest.  The ST subspecies noted in Fig 3.2 were consistent with the findings from 
LC ESI-MS/MS analysis of lipid extracts of equivalent tissues, however, one can also 
confirm the structural assignments by imaging tandem mass spectrometry. For this 
analysis, the tumor samples were analyzed using ABI Q-STAR and the spectra for the 
putative ST (d18:1/C16:0, m/z 778.6) and the unidentified ion with m/z 885.6 are shown 
in Figure 3A and B, respectively.   
The product ion scan spectrum of the ion with m/z 778.6 in the negative ionization 
mode gave a highly abundant fragment ion of m/z 96.9552, corresponding to a sulfate 
group (HSO4).  A less abundant fragment ion at m/z 241.0047 also appears from 
cleavage to release the sulfated sugar headgroup as shown (Fig 3.3A). The accurate mass 
for the presumed precursor ion d18:1/C16:0 ST, [(M-H)-, C40H76N1S1O11], was 778.5056 
and was within 15 ppm of the theoretical mass of 778.5144.  Similarly, the observed 
mass for the sulfated carbohydrate (C6H9SO8), 241.0047 and sulfate group, 96.9552, were 
less than 10 ppm different from the theoretical masses, 241.0024, 96.9601, respectively. 
 
 64 
Therefore, the structure of m/z 778.6 is consistent with ST (also called SM4 sulfatide, 
HSO3-3Galβ-1Cer) with a d18:1/C16:0 ceramide backbone. A similar fragmentation has 
been seen in brain tissue (198, 214, 215). 
The cleavage products from the m/z 885.6 precursor ion (Fig 3.3B) included a peak 
for m/z 241.0131, but did not show an ion of m/z 96.9 above background, suggesting that 
it was not a sulfatide (additionally, the mass difference between what was observed and 
the theoretical mass of a sulfated sugar is much larger than expected).  A much closer fit 
is obtained when a phosphoinositol head group is considered (C6H10PO8, m/z 241.0118).  
A possible structure for this ion has been drawn above the spectrum in Fig 3.3B (a 
phosphatidylinositol with C18:0 and C20:4 as the fatty acid) with cleavages that might 
account for the observed product ions, in agreement with what has been seen by others 
using MALDI for tissue imaging (216). 
 
3.4.4 Histological localization of ST in serous papillary ovarian carcinoma tissues by 
MALDI TIMS 
To visualize the localization of ST across the entire thin section, the relative ion 
abundances of the major ST (m/z 778.6, 888.6 and 890.6 correspondingly to d18:1/C16:0-, 
d18:1/C24:1-, and d18:1/C24:0-ST, respectively) collected at 60 µm intervals were 
plotted for the entire x,y field as shown in Fig 3.4.  As noted above for the H&E stained 
image (Figure 4A), there are regions with typical fibrovascular stroma (“a”) and 
malignant epithelial cells (“b”) as well as a few spaces with no visible cells (“*”).  For 
ease of comparison, dashed lines have been traced around the stromal regions and these 





Fig 3.3.  MALDI MS/MS spectra for two of the ions from Figure 2 (m/z 778.6 and 
885.6).  A thin section from an ovarian tumor was analyzed by MALDI imaging mass 
spectrometry as described in Fig. 2 except that the sample was analyzed using a hybrid 
quadrupole time-of-flight mass spectrometer (ABI Q-STAR) in negative ionization mode 
with selection of the shown parent ions (m/z 778.6 in panel A and 885.6 in panel B) for 
fragmentation and analysis of the product ion spectra shown here.  On the basis of the 
shown fragmentation schemes, the m/z 778.6 ion was identified as a d18:1/C16:0 






three ST are seen in most of the tissue regions identified as ovarian epithelial carcinoma, 
in strong contrast with the stroma, which were essentially free of ions with m/z 778.6, 
888.6 or 890.6 (Fig 3.4 B-D).   These data establish that the ST are derived primarily 
from the malignant cells rather than from other regions of the tissue.  This was also 
established by selecting spectra specifically located in stroma versus regions defined as 
epithelial ovarian carcinoma and determining the ion intensities of the ST in those 
regions (Fig 3.5).  A similar analysis of thin sections from normal ovarian tissue did not 
detect ions with the m/z of any of these ST, but PI was detectable and served as a positive 
control (Fig 3.6). 
 
3.4.5 Differences in gene expression between human surface ovarian epithelial cells 
and serous papillary ovarian carcinoma tissue  
To complement these mass spectrometric analyses as well as to provide information 
about a possible mechanism(s) for the appearance of ST (and to some extent, GalCer) in 
the ovarian cancer cells, the gene expression profiles were determined for healthy ovarian 
epithelial cells harvested from normal ovaries at the time of surgery using a pap brush 
and ovarian carcinoma epithelial cells collected by laser capture microdissection. After 
normalization, differences in expression of the genes for enzymes of the de novo 
sphingolipid biosynthetic pathway are displayed in a KEGG pathway pattern (213), as 
recently modified for sphingolipids (2) (Fig 3.7A).  It is evident from this depiction that 
mRNA for both of the enzymes that are uniquely required for ST biosynthesis, GalCer 
synthase and Gal3ST1 (3'-phosphoadenosine-5'-phosphosulfate:GalCer sulfotransferase), 





Fig 3.4.  Visualization of the localization of ST in a thin section of ovarian 
carcinoma tissue using MALDI TIMS.  Adjacent thin sections of ovarian cancer 
tissue was prepared as described in the text for H & E staining and histological 
identification of regions identified by “a” as non-malignant stroma, by “b” as serous 
papillary epithelial carcinoma, and by the asterisk “*” as regions where there were no 
cells.  Panels B-D show pseudo-color ion images where the relatively intensity of the 
labeled m/z (B, m/z 778.6; C, m/z 888.6; and D, m/z 890.6) using the heat map scale 
between panels C and D. Distinctive features in panel A have been manually traces with 
dashed lines, which have been superimposed on panels B-D to aid in comparison of the 







Fig 3.5.  Analysis of consecutive MALDI tissue imaging mass spectrometry (TIMS) 
spots through regions of the tissue that have been characterized as non-malignant 
stroma or carcinoma.   Panel A shows the approximate regions where the samples 
were irradiated with the N2 laser and spectra were obtained; the H & E stained thin 
section is from Fig. 4 of the manuscript.  Panel B shows the distribution of the 
intensities of the ions in these regions and the mean ± SE. The P value of the difference 
in the mean ion intensity of the carcinoma region versus the stroma was analyzed by 














Fig 3.6.  Visualization of phosphatidylinositol and sulfatides (ST) in a thin section 
of normal ovarian tissue using MALDI TIMS.  Adjacent thin sections of normal 
ovarian tissue was prepared as described in the text for H&E staining (A) and 
pseudo-color ion images for phosphatidylinositol (B) as a postive control (m/z 886.0 at 
the instrument calibration used for this image) and ST (at m/z 778.6, C; m/z 888.6, D; and 
m/z 890.6, E) using the shown heat map scale. Ovarian tissue in panel A have been 







whereas the alternative pathways for Cer metabolism (to sphingomyelin, SM, and GlcCer) 
are lower.  Therefore, from these findings, it would be predicted that GalCer and ST 
would be higher in the ovarian epithelial carcinoma cells.  
Two other differences are noteworthy in Fig 3.7A, a higher expression of two of the 
ceramide syntases (CerS3 and CerS4), that are thought to be capable of producing Cer 
with very-long-chain fatty acids (i.e., >22 carbon atoms) (33), and DES2, a 
dihydroceramide desaturase that is bifunctional as a desaturase to produce Cer and as a 
4-hydroxylase to produce phytoceramides (217).  The lower panels of Figure 7 show the 
subspecies distribution of the ST in the healthy ovarian epithelial cells (3.7B) and the 
ovarian epithelial carcinoma cells (3.7C).  It is noteworthy that the subspecies 
composition matches the CerS expression data in that most of the ST in the cancer cells 
have very-long-chain Cer (3.7C) whereas the predominate Cer for the normal 
cells—albeit in low amounts overall—has the C16-backbone (3.7B). MALDI TIMS 
analysis of other tumor samples also found that very-long chain ST co-localized with 
cancer cells (data not shown). We have not noted phytoceramide backbones in any of the 
samples analyzed, as might have been implicated by elevated DES2 (as both a desaturase 
and hydroxylase) (217).   
It is evident from Fig 3.7C (and Fig 3.1), that there is a high degree of subject to 
subject variation in the amounts of GalCer and ST.  To determine if there is a similar 
variability in the mRNA levels for the synthases for GalCer and ST, the normalized 
microarray data for the individual subjects are displayed in Fig 3.8A.  This comparison 
shows that the majority of the tumors have higher amounts of one or both of these 




Fig 3.7. Differences in the level of expression of genes for sphingolipid biosynthesis 
through ST, and the ST subspecies distribution of twelve normal human surface 
ovarian epithelial cells and epithelial ovarian tumors.  The relative levels of mRNA 
for the shown steps in the de novo sphingolipid biosynthesis pathway were analyzed for 
twelve normal human surface ovarian epithelial cells and twelve epithelial ovarian tumor 
cells using Affymetrix HG U133 Plus 2 Gene Chips for expression analysis. The average 
levels of expression for these genes were imported into a KEGG style pathway heatmap 
(prepared using the GenMapp pathway tool described in the text and reference (2)).  The 
difference of gene expression are represented by the color scale in panel A (red = higher 
for ovarian cancer vs. normal cells; green = lower for ovarian cancer vs. normal cells). 
The lower panels show the amounts and subspecies distribution of ST based on 
differences in the fatty acid chain length of the Cer backbone as measured by LC 





Fig 3.8A), but there is also subject to subject variability in the relative expression levels. 
The sum of GalCer synthase plus Gal3ST1 mRNAs in the arbitrary units from the 
microarray analysis was 4-fold higher for the ovarian cancer tissue than the normal (i.e., 
260 ± 46 versus 62 ± 13, mean ± SE, n= 12 of each, P=0.0003).  This is consistent with 
the metabolite data from the LC ESI-MS/MS analysis, which have been replotted in Fig 
3.8B as the sum of GalCer plus ST (with mean ± SE of 49 ± 14 versus 9 ± 2.0 pmol/mg 
protein for the ovarian cancer tissue than the normal, respectively) (P=0.0002, n=12 of 
each).  Note that it is, unfortunately, not possible to compare these results for individual 
subjects in panels A and B of this figure because they are from different groups.  
 
3.4.6 Elevated sulfatides in serum from ovarian carcinoma patients 
To determine if ST are also elevated in serum from patients with ovarian cancer, the 
ST of 12 normal women and 12 patients with serous papillary ovarian carcinoma were 
analyzed by LC ESI-MS/MS.  The amounts of very-long-chain ST were higher in serum 
from the cancer patients, with the amounts (pmol/ml as the mean ± SE, n=12 for each) for 
the cancer patients versus normals being: 15.9 ± 1.7 versus 10.7 ± 0.9 for d18:1/C20:0 ST 
(P=0.006); 26.3 ± 4.0 versus 20.7 ± 2.9 for d18:1/C24:1 ST (P=0.10); and 8.8 ± 1.2 
versus 5.3 ± 1.2 for d18:1/C24:0 ST (P=0.03); whereas, d18:1/C16:0 ST were not 
different (17.0 ± 2.5 versus 16.4 ± 2.4, P=0.44) (Fig 3.9).  This distinction between 
very-long-chain ST and the C16-ST subspecies in serum is interesting because it 
resembles the prevalence of very-long-chain ST (Fig. 3.7C) and the higher CerS3 and 4 





Fig 3.8. Variability in the level of gene expression of the synthases for GalCer and 
ST (A), and in the amounts of GalCer + ST in normal or ovarian carcinoma tissue 
(B).  Microarray data for the mRNAs for the synthases for ST (Gal3ST1) and for GalCer 
(GalCer synthase) for each of the 12 normal and ovarian cancer tissues (obtained by laser 
capture microdissection) are shown in panel A (White color in columns shows Gal3ST1; 
black color in columns shows GalCer synthase).  Panel B shows the amounts of GalCer 
+ ST for another 12 normal and ovarian cancer tissues (the same as the source of the data 
























Fig 3.9. Elevation of sulfatides in serum from ovarian carcinoma patients  
ST were extracted from serum for 12 women whose ovarian tissues scored as histological 
normal or as ovarian cancer (serous papillary epithelial carcinoma from stage Ic to stage 
IV) then analyzed by liquid chromatography electrospray ionization tandem mass 
spectrometry as described in the text and references (177, 178).  Shown are mean ± SE 
for subspecies of ST in serum from normal women versus patients for cancer. P values 
for subspecies (C20:0ST, C24:1ST and C24:0 ST) were calculated by using one-tailed 







By combining complementary profiling technologies, metabolite analysis by mass 
spectrometry with analysis of gene expression by laser capture microdissection, this study 
achieved its original goal of rigorously establishing that ST are elevated in ovarian cancer, 
as had been suggested by an earlier investigation (207).  LC ESI-MS/MS provided 
quantitative and structure-specific information about the ST as well as its precursor 
GalCer in the tumors, and MALDI TIMS localized the ST to regions identified as ovarian 
epithelial carcinoma versus surrounding stroma and normal ovarian tissue.  The gene 
expression analysis supported this conclusion by finding higher amounts of mRNA’s for 
both of the key enzymes of ST biosynthesis, GalCer synthase and Gal3ST1, in the 
epithelial ovarian carcinoma cells versus normal ovarian surface epithelial cells.  In 
addition, the carcinoma cells had greater expression of the mRNA’s for two Cer 
synthases (CerS3 and 4) that produce very-long-chain-Cer, which were prevalent in the 
ST of most of the ovarian cancer samples.  Thus, the elevation of very-long-chain-ST in 
epithelial ovarian carcinoma cells is likely a consequence of these gene expression 
changes.    
It is interesting that only a few of the ovarian tumors had higher amounts of GalCer 
than ST, and although individuals in panels A and B of Figure 8 cannot be directly 
compared, that there were some subjects with elevations in mRNA for GalCer synthase 
but not Gal3ST1 (Fig 3.8).  The simplest hypothesis to connect these observations is 
that GalCer mainly accumulates when there is insufficient Gal3ST1 to convert it into ST.  
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This might also account for the finding in another type of ovarian cancer, mucinous 
cystadenocarcinoma, that both GalCer, and to a lesser extent ST, are elevated (218). 
If detection of ST reflects early stages of ovarian cancer, as has been suggested 
previously (207), then ST might be a useful biomarker to monitor in ovarian biopsy 
samples, and perhaps others where elevations in ST have been noted, such as colorectal 
(173), hepatocellular (204), renal (205), brain (219) and small-cell lung cancers (206).  
This could be relatively easy if mass spectrometry becomes more widely applied to 
histologic analysis of biopsy samples (220), or if ST are useful as biotargeting ligands for 
other evolving tumor imaging (and possibly therapeutic) technologies, such as the use of 
nanoparticles (221). 
The consequence(s) of the elevation in ST in ovarian cancer are not known, but by 
analogy might affect the metastatic potential of tumors because ST and other sulfated 
glycolipids have been reported to participate in the metastasis of colorectal 
adenocarcinoma (173) and KHT fibrosarcoma cells (222).  ST are thought to facilitate 
metastasis as ligands for selectins (223), but they also interact with other extracellular 
proteins such as laminin and thrombospondin (224).  ST additionally affect the immune 
system, altering the phenotype of macrophages (225), which have been associated with 
ovarian cancer invasion and metastasis (226).  It should also be borne in mind that some 
of the cancer-relevant targets of ST might be intracellular because ST bind to the 
N-terminal domain of sphingosine kinase 2 (227), an enzyme that produces sphingosine 
1-phosphate and plays many important roles in cancer (228), including regulation of 
histone acetylation (229). 
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The finding that some of the very-long-chain subspecies of ST are elevated in serum 
from ovarian cancer patients further confirms that ST metabolism is abnormal in this 
disease, and raises the possibility that these compounds might have utility as serum 
biomarkers.  They are not likely to be useful as simple biomarkers because the 
elevations are modest and variable.  Nonetheless, if their elevation reflects a important 
tumor phenotype, such as metastatic potential, they could be valuable for predictive of 
disease progression, as previously suggested (207).  Now that elevation of ST has been 
verified, larger studies would be warranted to determine whether they are highest in 






Regulation of C18-ceramide and galactosylceramide biosynthesis via 





Overexpression of the SPTLC1 and SPTLC2 subunits of serine palmitoyltransferase in 
Hek293 cells (called SPT1/2 cells) elevates all subspecies of ceramide (Cer) but produces 
disproportionately higher amounts of C18- (N-stearoyl-) Cer and galactosylceramides 
(GalCer). These are interesting changes because Cer is known to inhibit trafficking from 
the ER to Golgi, and both of these sphingolipid subspecies might increase if there is a delay 
in exit of vesicles from the ER because GalCer is only synthesized in the lumen of the ER 
and the Cer synthase that makes C18-Cer (CerS1) is found in both ER and Golgi but is 
proteolytically degraded in the latter.  To test this hypothesis, both cell types were 
transfected with VSVG-ts045, a GFP-tagged protein that is retained in the ER at 40°C and 
proceeds to the Golgi when the temperature is lowered.  As predicted, VSVG-ts045 took 
twice as long to appear in the Golgi in SPT1/2 versus Hek293 cells. The transport rate for 
CerS1 was next analyzed using fluorescence recovery after photobleaching, and the t1/2 for 
recovery of CerS1-GFP fluorescence in the Golgi was considerably faster for Hek293 cells 
(1.3 min) than for SPT1/2 cells (4.4 min); furthermore, inhibition of SPT by myriocin 
increased the t1/2 to 2.5 min in SPT1/2 cells, which confirms that the slower ER/Golgi 
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transport is related to the elevated sphingolipid biosynthesis in SPT1/2 cells. To test the 
complementary hypothesis that impairment of ER/Golgi trafficking would elevate 
C18-Cer and GalCer, Hek293 cells were transfected with dominant negative Sar1a , which 
increased both subspecies as predicted.  A similar result was obtained when cells were 
treated with brefeldin A (BFA) to merge the ER and Golgi.  Indeed, BFA induced GalCer 
biosynthesis in not only this but also other cell lines that are not known to make substantial 
amounts of GalCer (Hela cells, HepG2 cells and HL60 cells); therefore, the capacity to 
synthesize GalCer is apparently widespread but latent, and production of GalCer under 
conditions where cell trafficking is altered might be more common than is currently 
appreciated.  In summary, these studies have uncovered that elevation of de novo 
sphingolipid biosynthesis can affect the rate of ER/Golgi trafficking, which in turn, can 
affect the types of sphingolipid subspecies made by the cells.  
 
4.2 Introduction 
Ceramides (Cer) are the backbones of complex sphingolipids which are important 
for cell structure as well as modulators of many cellular processes including proliferation, 
differentiation, senescence and apoptosis (1, 230-232).  Cer are biosynthesized in 
mammals by six ceramide synthases (CerS) that have different preferences for the fatty 
acyl-CoA donor of the acyl side chain (15, 31-34).  Biosynthesis of the specific Cer 
subspecies is apparently important because aberrant expression of the CerS that utilizes 
stearoyl-CoA to form C18-(dihydro)ceramide(34), CerS1  has not only been found in 
head and neck squamous cell carcinoma, but restoration of C18-Cer biosynthesis by 
transfection with CerS1 inhibited cell growth and induced apoptosis in this carcinoma (61, 
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233).  In addition, overexpression of CerS1 in Hek 293 cells sensitized them to a wide 
range of anti-cancer drugs (40).  
Studies of CerS1 have uncovered that it is translocated from the endoplasmic 
reticulum (ER) to the Golgi apparatus where it is turned over by ubiquitination and rapid 
proteasomal degradation (41, 234), whereas, there is no evidence for this occurring with 
CerS5, for example (41, 234). The ER and Golgi are also where Cer can be glycosylated 
to galactosylceramide (GalCer) by galactosylceramide synthase in the lumen of the 
endoplasmic reticulum (106) or to glucosylceramide (GlcCer) by glucosylceramide 
synthase (GlcCer synthase) on the cytosolic side of the Golgi apparatus (235).  This, too, 
is an important metabolic branchpoint because GalCer is not prevalent in all cell types (it 
is, for example, a major component of the myelin sheath and contributes to neuronal 
structure and signal conduction) (236), and GlcCer has been found to stimulate cell 
proliferation (237, 238) and cellular differentiation (239, 240), specifically in neuronal 
cells (241, 242). 
In studies of a Hek293 cells stably overexpressing both subunits of serine 
palmitoyltransferase that are necessary for activity (i.e., SPTLC1 and SPTLC2, thus, these 
cells are referred to as SPT1/2 cells), we have found that these cells have not only elevated 
Cer but also disproportionately high C18-Cer and GalCer.  Since Cer (243) and a number 
of other sphingolipids (244) are known to inhibit ER to Golgi trafficking, this study 
examined whether the biosynthesis of these subcategories of sphingolipid can be affected 
by modulation of ER to Golgi trafficking, and if this is likely to explain the aberrant species 




4.3 Methods and Materials 
4.3.1 Materials 
The Hek293, Hela, HepG2, Hl-60 cell lines were obtained from the American Type 
Culture Collection (Manassas, VA).  All tissue culture plastic ware was obtained from 
Corning (Corning, NY). Fetal bovine serum was supplied by Hyclone (Logan, Utah). 
C6-NBD-Cer was from Avanti Polar Lipids (Alabaster, AL). Protease inhibitor cocktail 
was obtained from Roche (Indianapolis, IN).The internal standard cocktail was provided 
by Avanti Polar Lipids (Alabaster, AL) certified to be > 95% purity. The HPLC grade 
solvents (acetonitrile, chloroform, hexane and methanol, as well as formic acid (ACS 
grade), were obtained from VWR (West Chester, PA), and acetic acid (ACS grade) was 
obtained from Fischer (Pittsburg, PA). 
 
4.3.2 Cell culture  
Human embryonic kidney 293 cells (Hek293) (ATCC, Manassas, VA) and Human 
embryonic kidney 293 overexpressing SPTLC1 and SPTLC2 (STP1/2) (a gift from David 
Uhlinger, Johnson & Johnson, R.W South Raritan, NJ 08869), were maintained in 
Dulbecco Modified Eagle Medium with Ham's F12 Nutrient Mixture (DMEM/F12) 
(Gibco, Carlsbad, CA) media supplemented with 10% fetal bovine serum (Hyclone, Logan, 
Utah), and 1.2 g/l sodium bicarbonate. The cells were incubated at 37°C in a humidified 
incubator with an atmosphere containing 5% CO
2
. HepG2, Hela cell lines were maintained 





4.3.3 Electrospray tandem mass spectrometry for sphingolipids  
Cells were grown in 100-mm culture dishes, washed with ice-cold phosphate buffered 
saline (PBS buffer), then harvested by rubber-policeman, and collected. The cell pellets 
were extracted and analyzed for sphingolipids using the conditions as described in the 
paper (177-179). 
 
4.3.4 VSVG-GFP trafficking 
Assay was performed as described (244-246). Cells seeded on the 24-well-plate 
overnight were transfected with pEGFPdKA206K-N1-VSVG tsO45 plasmid (a gift from 
George Patterson, 9000 Rockville Pike Room 101, MSC 5430 Bethesda, MD 20814) 
by Genejuice reagent (Novagen, Gibbstown, NJ) and cultured on poly-D-lysine-coated 
coverslips at 40°C for 48 hours. The cells were then shifted to 32°C for 0, 5, 10, 15, 20 
mins. Cells grown on coverslips were washed with PBS twice, fixed immediately with 
1.5% formaldehyde solution in PBS for 5 min at room temperature. Coverslips were 
mounted on glass slides with a drop of fluoromount-G, and images were collected by 
Zeiss LSM 510 laser confocal microscope with a X40 objective lens.  
 
4.3.5 hCerS1-GFP construct 
Human CerS1 (Genebank access number: BC022450, Open Biosystem, Huntsville, 
AL) was cloned into EcoR V site of mammalian expression pEGFP-N1 vector (Clontech, 
Mountain View, CA ) with kanamycin selection to generate constructs with GFP 




4.3.6 Living-cell image  
Assay was modified as described (246). Cells were cultured on poly-D-lysine-coated 
(BD Bioscience, San Jose, CA) 45 mm coverslips and then transiently cotransfected with 
CerS1-GFP and pDsRed-Monomer-Golgi vector (Clontech) with Genejuice transfection 
reagent (Novagen) at 37°C. After 6h, the cells were cultured with fresh medium with or 
without myriocin (10µM) for another 18h.  Then the coverslip was assembled with flow 
chamber system (Bioptechs, Butler, PA), connected with flow chamber controller to 
maintain the temperature at 37°C. The images were taken by Zeiss LSM 510 confocal 
microscope system. The GFP molecule was excited with the 488 line of a krypton-argon 
laser and the images made with a 515-540 filter. The pDsRed-monomer was excited with 
helium laser and the images made with a 580 filter. The Golgi area was identified by 
pDsRed-Monomer-Golgi. The GFP fluorescence at Golgi was photobleached by a 
krypton-argon laser, and the recovery of GFP fluorescence was observed by seconds. All 
images were taken with a X40 objective lens. Hek293 cells or SPT1/2 cells without 
transfection were prechecked to adjust the backgrounds of autofluorescence. 
 
4.3.7 Inhibiting ER-Golgi trafficking by dominant negative Sar1a mutant 
Hek293 cells seeded on 60mm plates overnight and transfected with 
pcDNA3.1-Sar1a-uT, 39N, 79G, 134I ( a gift from Jeanne Matteson, the Scripps 
Research Institute, Dept of Cell and Molecular Biology, La Jolla, Ca 92037) and/or 
CerS1-GFP vector by Genejuice transfection reagent according to the manuscript 
description. Cells were incubated at 37 °C. After 24h, cells were collected, lipids were 
extracted and analyzed by mass spectrometry as described above. 
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4.3.8 Brefeldin-A treatment  
Brefeldin-A (BFA) powder (Sigma-Aldrich, St. Louis, MO) was dissolved in 
ethanol and stored at -20°C. Cells were seeded at 2.5x10^6 cells per 10 ml in 100mm 
dish and grown for 2 days. Cells were treated with 5 µM BFA and incubated 0, 1, 3, or 6 
hours. Cells were collected, extracted and analyzed by mass spectrometry as described 
above.   
 
4.3.9 Semi-quantitative real-time PCR (QRT-PCR)  
Total cellular RNA was isolated by GeneElute mammalian total RNA Kit (Sigma) 
according to the manufacturer’s directions, and RT on a MJ mini cycler by reverse 
transcription Kit (Applied Biosystem, Foster City, CA) as follows: a 20 µg reaction 
containing 0.6 µg of RNA, 2.5 µM  random hexamer (or oligo dT) primers, 2.5mM dNTP, 
5mM MgCl, 0.4Unit  RNase inhibitors, 1.25 Unit Taqman reverse transcriptase was 
reverse transcribed in a PCR thin-layer tube at 25 oC for 10 min, 48 oC for 30 min and 95 oC 
for 5 min. The cDNA was stored at -20
 o
C.  The following primers were used: 
humanβ-actin, forward 5’- TCCTGTGGCATCCACGAAACT-3’ and reverse 
5’-GAAGCATTTGCGGTGGCAGAT-3’ having a melting temperature of 55°C.  
GalCer synthase: forward 5’ AGAAGCTTTCGGAAATTCAC3’; reverse 
5’AGTATAACAAGGCAGCACCA3’ (amplifies a fragment 188 bp long) having a 
melting temperature of 54°C. QRT-PCR primers for GlcCer synthase sequences are, 
forward 5’ CTGCCACCTTAGAGCAGGTA3’; reverse 5’ 
TCTTCGGCAATGTACTGAGC3’ (amplifies a fragment 166 bp long) having a melting 
temperature of 56°C.  Each forward and reverse primer (5 µM, 1.5ul ) and 2x SYBR 
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Green PCR master mix were mixed with 4 µl of cDNA  in a 96-well PCR plate. cDNA 
was amplified for 40 cycles by denaturation at 95 
o
C for 30 s, primer annealing at each 
specific melting temperature for 20s and elongation at 72 
o
C for 20s in an iCycler iQ 
Real-Time Detection System (Bio-Rad, Hercules, CA ). All data were normalized using 
β-actin. 
 
4.3.10 GalCer synthase and GlcCer synthase enzymatic assay  
The enzymatic assay was adapted from Abelson, et al (172). Cells were pelleted and 
resuspended into 400 µl of homogenization buffer ((HB) 250 µM sucrose, 10 µM HEPEs 
NaOH pH 7.2, 1 µM EDTA), and homogenized by sonication for 30 sec 3 times. The cell 
mixture was centrifuged for 15 min at 400 g and 4°C to remove nuclei and unbroken cells 
for isolation of postnuclear supernatant (PNS). Protein in the PNS was measured using 
the BCA assay. Equal volume of reaction mixture ( HB containing 2% (w/v) BSA, 4 mM 
UDP-Glc or UDP-Gal, 4 mM MgCl
2
, 4 mM MnCl
2





-Cer)) was added to the adjusted PNS, and incubated at 37°C 
for desired time. The reaction was stopped by transfer into cold methanol. The samples 








(800:200:5) (v:v:v) at a flow rate of 1 ml/min and a Nova Pak C
18 
4 micron cartridge 
(Waters, Milford, MA). 
 
4.4 Results 
4.4.1 Higher amounts of C18-Cer and GalCer in the SPT1/2 cells  
Serine palmitoyltransferase (SPT) is the first enzyme in the de novo sphingolipid  
 
 86 
biosynthesis pathway. Stably transfected SPT units 1 and 2 in the Hek293 cell line 
provided a unique opportunity for study the downstream metabolites. As predicted, the 
total Cer were increased from 152 ± 27 pmol/mg of protein in Hek293 cells to 1142 ± 90 
pmol/mg of protein in SPT1/2 cells (Fig. 4.1A). Ceramides increased about 9 fold in 
SPT1/2 cell in comparison with Hek293 cells. The proportion of C16-Cer, C20-Cer, 
C22-Cer, C24:1-Cer, C24-Cer was 30%, 2%, 10%, 14%, 21% in Hek293 cells, versus 
38%, 1%, 7%, 18%, 23% in SPT 1/2 cells.  The proportion of C18-Cer changed from 8% 
in Hek293 cells to 18% in SPT1/2 cells. C18-Cer increased from 20 ± 3 pmol/mg of 
protein in Hek293 cells to 218 ± 16 pmol/mg of protein in SPT1/2 cells. It is about 11-fold 
change. C16-Cer increased from 97 ± 15 to 347 ± 12 pmol/mg of protein, but it was 
3.5-fold-change and the proportion of C16-Cer increased only from 30% to 38% (Fig. 
4.1B). Compared with other subspecies of ceramides, a disproportionate increase in 
C18-Cer was observed in SPT1/2 cells (Fig. 4.1B).  
The total GalCers in the Hek293 cells were 21 ± 9 pmol/mg of protein, while total 
GalCer were 129 ± 23 pmol/mg of protein in SPT1/2 cells. Total GalCer increased more 
than 6 fold in SPT1/2 cells. In Hek293 cells, the amount of C16, C18, C24:1 GalCer were 
8.1 ± 4.6, 0.4 ± 0.4, 5.5 ± 1.7 pmol/mg protein. But in SPT1/2 cells, C16:0 GalCer was 
72 ± 10 pmol/mg protein, which was about 9 fold increase; C18CalCer was 19 ± 4 
pmol/mg protein, which was 47 fold increase; C24:1CalCer was 20 ± 2 pmol/mg protein, 
which was about 4 fold increase (Fig. 4.1C).   
 





Fig. 4.1 The change of sphingolipids in Hek293 and SPT1/2 cells 
Hek293 and SPT1/2 cells were collected, lipids were extracted and quantitated by LC-ESI 
MS/MS . Shown are the means for triplicate samples of each group, with analytical SD of 
10 to 20% when data is above 5pmol/mg protein.  
(A)Total cellular amounts of ceramide in Hek293 and SPT1/2 cells  
(B)Percentage of subspecies of ceramides in a doughnut form in Hek293 and SPT1/2 cells 




Cer is known to inhibit trafficking from the ER to Golgi (243). Both Hek293 and 
SPT1/2 cell types were transfected with GFP-tagged temperature-sensitive protein 
VSVGts045 vector. VSVGts045 misfolds and is retained in the ER at 40°C, but rapidly 
folds and exits the ER, moves to Golgi when the temperature is decreased to 32° (246) . 
GFP tag of VSVGts045 does not alter protein transport or function (247). In agreement 
with previous studies, exportation of VSVG-ts045 from ER to the Golgi was rapid and 
nearly completed within 15 min upon shifting from 40 to 32°C in Hek293 cells. However, 
SPT1/2 cells showed a significant delay in the appearance of VSVG-ts045 in the Golgi 
(Fig. 4.2B).  
 
4.4.3 Elevation of C18-Cer by impairment of CerS1 trafficking between ER and Gogi 
CerS1 translocated from ER to Golgi apparatus in response to different types of 
stresses. Without exogenous stress, some low basal level of ER to Golgi translocation is 
also observed (40, 41, 234). CerS1 shows multiple subcellular locations. To test whether 
CerS1 trafficking from ER to Golgi is slower in SPT1/2 cell than Hek293 cells, Hek293 
and SPT1/2 cells were cotransfected with CerS1 with GFP tag at the C terminal 
(CerS1-GFP) and the pDsRed-Monomer-Golgi vector encoding human beta 1, 4- 
galactosyltransferase which contains the membrane-anchoring signal peptide targeting the 
trans-medial region of Golgi. The CerS1-GFP in the Golgi area was photobleached and the 
recovery of CerS1-GFP in the Golgi was observed by confocal microscope by seconds. 





Fig. 4.2 Ceramide(s) alters the ER-to-Golgi trafficking  
Cells were transfected with VSVG-ts045 and incubated in DMEM/F12 for 48 h at 40°C, , 
shifted to 32°C for the indicated times, and images were taken by confocal microscopy.  
(A) Image of VSVG-ts045 protein in Hek293 cells and SPT1/2 cells (Scale bar: 10µm)  











Fig. 4.3 Reapperance of CerS1-GFP in Golgi after photobleaching 
The cells growing on 45mm coverslips were transfected with CerS1-GFP and 
pDsRed-Monomer-Golgi vector. After 6h, medium were removed. Fresh medium with or 
without 10 µM myriosin added and cells were continued incubation for 18 hours at 37°C. 
Then cells growing on the coverslip were assembled with flow chamber system which was 
connected with flow chamber controller to maintain the temperature at 37°C. CerS1-GFP 
in the Golgi apprartus was photobleached under the indication of pDsRed-Monomer-Golgi. 
All images were taken by Zeiss LSM 510 confocal microscope system. 
(A) Image of CerS1-GFP before or after photobleaching in Hek293 and SPT1/2 cells 
(Scale bar: 5µm.The arrow pointed to the photobleached Golgi area in the cells) 
(B) CerS1-GFP fluorescence recovery after photobleaching in the Golgi  
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cell was 4.42 ± 0.83 min, which was slower than that in Hek293 cells (1.26 ± 0.37 min) 
(Fig. 4.3B). When SPT1/2 cells were treated with myriocin, the inhibitor of serine 
palmitoyltransferase, the half time of reappearance of CerS1-GFP in the Golgi became 
faster (2.54 ± 0.57 min) (Fig. 4.3B).  
It has been reported that the CerS1 is proteolytically degraded in the Golgi apparatus 
to a C-terminal fragment (41). To determine whether CerS1 location affects the C18-Cer 
biosynthesis, a dominant-negative Sar1a mutant (pcDNA3.1-Sarla-uT, 39N, 79G, 134I) 
was used to block the protein trafficking between ER and Golgi. It is known that newly 
synthesized proteins and recycling proteins are sorted into ER-derived COPII-coated 
vesicles (248). The COPII coat machinery includes the soluble GTPase Sar1 and two 
cytosolic protein complexes, Sec23/24 and Sec13/31. Activation of Sar1 itself leads to 
the formation of ER-derived tubular domains which initiate cargo selection to Golgi 
(249). A negative-dominant Sar1a mutant has a preferential affinity for GDP and strongly 
inhibits vesicle budding from the ER (248).  
Normally C18-Cer is not a major subspecies in the wild type Hek293 cells, its 
amount are very low in Hek293 cells (Fig. 4.1B). To avoid the cellular amount of 
C18-Cer was covered by the background noise, Hek293 cells were transfected with Sar1 
mutant and/or CerS1-GFP vectors. Compared with the Hek293 cell expressing CerS1 
only, the Hek293 cell expressing CerS1 and dominant negative Sar1 mutant had 
evidently elevation of C18-Cer, which was increased from 567 ± 96 to 876 ± 13 pmol/mg 





Fig. 4.4 Elevation of C18-Cer after transfection of dominant-negative Sarla mutant 
Hek293 cell were transfected with only CerS1-GFP or CerS1-GFP and 
dominant-negative pcDNA3.1-Sar1a-uT,39N,79G,134I plasmid at 37°C for 24 hours, 
then cells were collected and subspecies of ceramide were analyzed by LC-ESI-MS/MS. 
Shown are subspecies of ceramide in Hek293 cell after transfected with CerS1-GFP and /or 
Sarla mutant. Shown are the means for triplicate samples of each group, with analytical 











4.4.4 Inhibition of ER/Golgi trafficking elevates GalCer biosynthesis  
As mentioned before, in comparison with Hek293 cells, SPT1/2 cells not only have 
higher proportions of C18-Cer but also show higher cellular amounts of GalCer. Since 
GalCer synthase is located in the lumen of the ER, our hypothesis is that the slow 
ER-Golgi trafficking rate may affect the GalCer synthesis in SPT1/2 cells. 
Dominant-negative Sar1a was used to block the protein trafficking between ER and 
Golgi in Hek293 cells. There was little increase of total GlcCer in the transient 
transfected Hek293 cells (Fig. 4.5A). On the contrary, the total GalCer in SPT1/2 cells 
was 87 ± 22 pmol/mg of protein; GalCer in Hek293 cells was only 12 ± 2 pmol/mg of 
protein, a 7-fold increase (Fig. 4.5B).  
To further test this hypothesis, Hek293 cells were treated with brefeldin-A (BFA). 
Cer are transported from ER to Golgi for sphingomyelin and GlcCer synthesis (45, 71); 
furthermore, the Golgi contains a UDP-Gal transporter (UGT1) that transfers UDP-Gal 
from the cytosol to the Golgi matrix for synthesis of complex glycosphingolipids such as 
lactosylceramide (250). BFA treatment induces Golgi fusion with the ER, allowing 
enzymes and substrates in the ER access to enzymes and substrates localized in the Golgi 
(251-253). When treated with 2 µM BFA for 1 h, Hek293 cells synthesized GalCer (Fig. 
4.6B). GalCer synthesis increased further with a higher concentration of BFA and with a 
longer time of incubation (Fig. 4.6B and D). GlcCer decreased in Hek293 cells incubated 
with 2 µM BFA for 1 h, the amount of the C16 GlcCer was initially 290 ± 69 pmol/mg of 
protein and decreased to 199 ± 36 pmol/mg of protein, and continued to decrease with 
use of a higher BFA concentration and longer incubation time (Fig. 4.6A and C).  





Fig. 4. 5 The effect of Sar1a dominant-negative mutant on monohexosylceramide in 
Hek293 cells and SPT 1/2 cells  Hek293 cell were transfected with dominant negative 
pcDNA3.1-Sar1a-uT, 39N, 79G, 134I plasmid at 37°C by genejuice for 24 hours, then 
cells were collected and subspecies of GalCer and GlcCer were analyzed by 
LC-ESI-MS/MS. Shown are the means for triplicate samples of each group, with 
analytical SD of 10 to 20% when data were above 10 pmol/mg protein (not shown). 









Fig. 4.6 The effect of BFA on the amounts of monohexosylceramides in Hek 293 cells 
Shown are cellular amounts of different GalCer and GlcCer subspecies in Hek293 cells. 
Hek293 cells were incubated with 0, 2µM, 5µM of BFA for 1h and 6h. Cells were 
collected, extracted. GlcCer and GalCer were measured by LC-ESI MS/MS. Shown are 
the means for triplicate samples of each group, with analytical SD of 10 to 20% when 
data were above 10 pmol/mg protein (not shown). (A), (B) Cells incubated for 1 h with or 
without BFA; (C), (D) Cells incubated with or without BFA for 6 h.  
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lines -- Hela, HepG2, and HL-60 cells that did not contain detectable GalCer under basal 
conditions. In all cases, treatment with 5 µM BFA for 6 h resulted in considerable 
increases in GalCer as measured by LC-MS/MS. For HeLa cells, the predominant GalCer 
species were C24:1 and C24:0 (87 ± 19 and 106 ± 34 pmol/mg of protein, respectively) 
(Fig. 4.7A); for HepG2 cells, the predominant species was C24:1 (230 ± 19 pmol/mg of 
protein) (Fig. 4.7B); and for HL-60 cells, the major species was C16 GalCer (81 ± 4 
pmol/mg of protein) (Fig. 4.7C). These results illustrate that the ability to synthesize 
GalCer exists in a range of cells in which GalCer is not normally detected.  
 
4.4.5 GalCer synthase and GlcCer synthase mRNA expression and enzyme activity in 
Hek293 and SPT1/2 cell 
To exclude the possibility that the appearance of GalCer in SPT1/2 cells was due to 
the difference of enzymatic activity of GalCer synthase in Hek293 and SPT1/2 cells, 
GalCer synthase and GlcCer synthase mRNA expression and enzyme activity in Hek293 
and SPT1/2 cells were measured.  
There does not appear to be any difference in the amount of GalCer synthase and 
GlcCer synthase mRNA in Hek293 and SPT1/2 cells by QRT-PCR (Fig. 4.8A). The 
activity of GalCer synthase and GlcCer synthase was measured through an in vitro assay 
utilizing NBD-C6-Cer in intact cells. The activities of GalCer synthase in Hek293 and 
SPT1/2 cells are comparable (1.0 ± 0.3 and 0.8 ± 0.3 nmol/min/mg of protein). The same 
is true for GalCer Synthase in Hek293 and SPT1/2 cells, which were 2.5 ± 0.7 and 2.1 ± 




Fig. 4.7 The effect of BFA on GalCer in Hela, HepG2, and HL-60 cells 
Shown are cellular amounts of subspecies of GalCer in Hela, HepG2, HL-60 cells.   
Cells were incubated with or without 5 µM concentration of BFA for 6 h and collected. 
The sphingolipids were extracted and analyzed by LC-ESI MS/MS as described in the 
text. Shown are the means for triplicate samples of each group, with analytical SD of 10 









Fig. 4. 8 Measurement of mRNA and in vitro enzymatic activity for GalCer synthase 
and GlcCer Synthase in Hek293 and SPT1/2 cells  (A) CalCer synthase and GlcCer 
Synthase mRNA expression (versus b-actin) analyzed by QRT-PCR 
(B) Shown are the GalCer synthase and GlcCer synthase in vitro enzymatic activity.  
Hek293 and SPT1/2 cells were permeabilized and incubated with NBD-C6-Cer and 
either UDP-Glc or UDP-Gal, then analyzed by HPLC with fluorescent detection of the 










These studies have established that modification of ER to Golgi trafficking using 
dominant-negative Sar1a, which is known to inhibit ER vesicle budding (248), or by 
treating cells with BFA, which causes mixing of the ER and Golgi (252, 253) elevates 
C18-Cer and GalCer biosynthesis in Hek293 cells.  Reciprocally, elevation of de novo 
sphingolipid biosynthesis slows ER to Golgi trafficking and, thus, elevates C18-Cer and 
GalCer synthesis.  ER to Golgi trafficking has long been known to be inhibited by 
exogenously added Cer (243, 254), thus, these studies have found that elevation of de 
novo biosynthesis can also affect the ER/Golgi transport. 
This is likely to account for the increased GalCer synthesis because GalCer synthase 
is located in the lumen of the ER (106), therefore, there is a greater opportunity for Cer to 
be galactosylated when it is retained in the ER longer.  This assumes that Cer can flip 
from the cytosolic to the luminal sides of the ER since Cer is made on the cytosolic side 
(106), and although the flip-flop rate for ER Cer is not known, the half-time for Cer 
flip-flop in a phosphatidylcholine bilayer is <1 min at 37 °C (255), therefore, it is 
plausible that this is fast enough. Correspondingly, GalCer was elevated in SPT1/2 cells, 
which have a slower ER to Golgi trafficking as assessed by the rate of appearance of 
VSVG protein in the Golgi after a shift to the permissive temperature (246).  
It was somewhat surprising that cells that usually contain barely detectable amounts 
of GalCer—not just Hek293 cells but also HepG2 and HeLa--have a very high latent 
GalCer synthase capability, as reflected by the very large amounts of GalCer that are 
made when they are treated with BFA (Fig. 4.7) and in vitro assays for Hek and SPT1/2 
cells.  We are not aware that others have reported that elevated de novo Cer biosynthesis 
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or disruption of ER to Golgi trafficking by dominant-negative Sar1a or BFA causes such 
large elevations in GalCer biosynthesis, however, most studies analyze only the ceramide 
monohexose (i.e., the sum of GlcCer and GalCer) in cells since these compounds have 
similar mobilities in most thin-layer chromatographic systems and are isobaric by mass 
spectrometry.  It is interesting to speculate that this latent capacity to biosynthesize 
GalCer exists so cells can make this type of sphingolipid when ER to Golgi trafficking is 
slowed, and thus, might have a physiologic significance. 
An explanation for the elevation in C18-Cer is less obvious, however, since CerS1 
has been recently been shown to be proteosomally degraded after translocation to the 
Golgi (41, 234), the inhibition of ER to Golgi trafficking will retain CerS1 in the ER 
where it has access to sphinganine made by de novo sphingolipid biosynthesis, and 
decrease its degradation.  Consistent with this hypothesis, CerS1 translocation to the 
Golgi was found to be slower for SPT1/2 cells than Hek cells as assessed by fluorescence 
photobleaching and recovery using GFP-tagged CerS1.  Furthermore, this is likely to be 
due to the suppression of trafficking by Cer since inhibition of de novo sphingolipid 
biosynthesis using myriocin increased the recovery rate for SPT1/2 cells toward that of 
Hek cells (Fig. 4.3).   
These findings illustrate the types of complexities that can be encountered when 
studying this pathway—with elevation of de novo sphingolipid biosynthesis by 
overexpression of SPT not only causing greater amounts of sphingolipids to be made, but 
also for the nature of the subspecies to shift as the higher amounts of the sphingolipids 




Overall conclusions and future perspectives 
 
These studies were intended to use novel technologies to gain new information 
about the specific molecular subspecies of sphingolipids that are found in selected 
biological systems as well as about where they are located, then to complement these 
investigations with studies of a not previously appreciated mechanism for regulation of 
Cer and GalCer biosynthesis—the rate at which newly made sphingolipids are trafficked 
from the ER to the Golgi.  The starting point for these studies was the recent availability 
of methods to analyze hundreds of sphingolipid subspecies (from sphingoid bases and 
other lipid backbones to more complex sphingolpids--SM, GalCer, GluCer, ST, and 
others) using electrospray ionization tandem mass spectrometry (ESI MS/MS) (177, 179), 
usually in combination with liquid chromatography.  
As one contemplates the application of these methods to study sphingolipids in a 
physiologic context, it becomes evident that a limitation of these methods is that the first 
step of the analysis is to grind and homogenize the tissue for lipid extraction, thus, losing 
information about the sphingolipid composition of different regions of the tissue.  To 
deal with this, I worked with Dr. Yanfeng Chen to develop an improved method for 
studying sphingolipids in tissues using tissue-imaging mass spectrometry (TIMS).  This 
first involved the development of a more effective method to deposit the MALDI matrix 
compound on the tissue slices (using an oscillating capillary nebulizer, OCN, matrix 
coating system), which was found to produce samples that could be used for 
visualization of multiple categories of lipids--sulfatides, gangliosides and 
 
 102 
phosphoglycerolipids, among others.  To demonstrate the utility of the technique, we 
analyzed brain slices from normal mice and mice with a genetic defect that serves as a 
model for Tay-Sachs/Sandhoff disease, and were able to show the localization of not 
only ganglioside GM2 but also subspecies of GM2 (e.g., with a d20:1 backbone) and 
other sphingolipids (e.g., G2A) in this disease model (194).  
In future studies, this technique could be used to study the molecular pathogenesis 
of these GM2 storage diseases, which is not clearly understood.  There is evidence 
linking inflammatory responses involving microglia and bone marrow-derived 
macrophages to neurological injury in GM2 gangliosidoses (256, 257).  For instance, 
activated microglial expansion, based on gene expression and histologic analysis, 
appears to precede massive neuronal death, and extensive microglia activation has also 
been detected in human cases of Sandhoff disease (161).  Consistent with this 
hypothesis, bone marrow transplantation of Sandhoff disease mice suppressed both the 
expansion of activated microglia and the neuronal cell death without detectable decreases 
in neuronal GM2 ganglioside storage (161).  At present, it is not known whether the 
lysosomal storage per se or signals from the surrounding milieu triggers the observed 
microglial activation, therefore, it would be helpful to apply MALDI TIMS to additional 
histological slices in mice (and humans, where possible) at different stages of disease, 
after intervention with bone marrow transplantation, etc. to determine which of the 
proteins and lipids have been normalized, thereby, possibly discovering useful 
biomarkers or insights into the mechanisms of the disease and its treatment.  
From a lipidomics perspective, it would be useful to analyze a broader profile of the 
sphingolipids in the tissues using more sophisticated techniques such as MALDI TIMS 
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MS/MS instead of only TIMS MS.  Analysis of Cer would be a good place to start 
because Cer has been suggested to be involved in the inflammatory reaction and to 
function as potential mediator of apoptosis in neurons, and it is known that TNF-α, IL-1 
and Fas/FasL, which are increased in tissue from neurodegenerative disorders, potently 
induce Cer production.  Cer, in turn, stimulates production of IL-2 and IL-6 (144-146), 
therefore, knowing the timing and localization of changes in this bioactive lipid might 
identify its role in disease pathogenesis.   This might also provide a link to other 
bioactive lipids that could be analyzed because gliosis is marked by the release of 
proinflammatory mediators such as prostanoids from activated microglia, which is 
known to be influenced by sphingomyelinase activation and Cer generation (258).  All 
in all, there might be many levels at which changes in Cer could play a role in this 
disease because Cer is a signaling mediator for many important processes, including 
dephosphorylation, mitochondrial depolarization and permeabilization, cytochrome c 
release and activation of caspase-3 (52), and changes in Bax level, leading to formation 
of Bax homodimers, mitochondrial permeabilization and neuronal death (53).  In 
preliminary studies, we have observed that Cer is higher in the cerebral cortex of the 
Tay-Sachs/Sandhoff mice than in the wild type.  Thus, future studies could focus on 
understanding whether Cer or its metabolites are involved in microglia activation and 
neuronal death using the same Tay-Sachs/Sandhoff disease model.  
Once these sphingolipidomics tools had been found to be successful in this model 
system, they were applied to ovarian cancer samples to determine if such a combined 
approach would provide insight into whether ovarian cancer cells differ in sphingolipid 
composition from neighboring non-cancerous tissue.  As described in chapter 3, these 
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studies used ESI-MS/MS to establish that ST and GalCer are elevated in ovarian 
cancerous tissue, then MALDI TIMS was used to establish that the ST are associated 
specifically with the regions of the ovarian tissue that bear the carcinoma.  These 
lipidomic findings were complemented by gene array data that revealed greater 
expression of mRNAs for GalCer synthase, GalCer sulfotransferase (Gal3ST1) and other 
enzymes of ST biosynthesis in epithelial ovarian carcinoma cells.  
There are many possibilities for why ST might be important in cancer.  Studies 
with a mouse colon carcinoma cell line, MC-38, noted that P-selectin ligands recognize 
and bind with sulfatides and thereby facilitate experimental metastasis in a syngeneic 
mouse model (223). Another study has shown that the presence of ST on tumors not only 
promotes apoptotic cell removal but also alters the phenotype of tumor-associated 
macrophages (TAM) (225). TAM within the tumor microenvironment facilitate 
angiogenesis and extracellular-matrix breakdown and remodeling and promote tumor cell 
motility (259, 260). Thus, it would be interesting to study whether ST in ovarian 
epithelial carcinoma cells induces phagocytosis, promotes the macrophage clearance of 
apoptosis tumor cells and modifies the ways that TAM respond to micro environmental 
factors in tumors by producing mitogens and humoral factors that stimulate angiogenesis.  
This approach could be applied to many types of cancer.  Higher expression of 
sulfatides in colorectal carcinomas and ovarian carcinomas has been correlated with poor 
prognosis (173) (261), therefore, colon cancer might be a sensible cancer type to study 
next.   
My finding that Hek293 cell line stably overexpressing serine palmitoyltransferase 
(SPT1/2 cells) display elevations in all subspecies of ceramide, but disproportionately 
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higher amounts of C18-Cer and GalCer, led to the interesting hypothesis that the is a link 
between de novo sphingolipid biosynthesis, ER/Golgi trafficking, and the types of 
sphingolipid subspecies.  Beside the implications of these findings for cell biology, which 
were already discussed in the chapter, this might also be important in diseases such as 
cancer.  C18-Cer plays an important role in squamous cell carcinomas of the head and 
neck (HNSCC), which are among the most aggressive group of cancers.  Studies by 
Ogretmen and others have found that C18-ceramide is significantly decreased in HNSCC 
tumors and that this is associated with the higher incidences of lymphovascular invasion, 
and pathologic nodal metastasis (233). Further experiments showed that overexpression 
of CerS1 resulted in the inhibition of HNSCC cell growth and enhanced 
chemotherapy-induced apoptosis in both UMSCC22A cells in situ and in HNSCC xeno 
grafts in vivo (61, 262).  Therefore, our finding that one can elevate this Cer subspecies 
by modifying the rate of ER/Golgi trafficking suggests that this might be another strategy 
for cancer control in head and neck cancer.  
Although the findings about GalCer and ER/Golgi trafficking have already been 
discussed, it is interesting to note that although hundreds (and possibly thousands) of 
studies have used BFA to study protein trafficking, synthesis, and structural changes in 
cells (263-265), none have been aware of this major perturbation of sphingolipid 
composition.  This underscores how many aspects of cell biology are incompletely 
understood for the lack of techniques that can measure changes in many of the 
compounds in cells.  In the case of GalCer, there are many ways that changes in its 
amount might be important in cell function, such as: a) to minimize the buildup of Cer, 
and thus avoid the cell toxicity of Cer; b) to serve as a signal to induce a cell response, 
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such as autophagy when there is a slowing of ER trafficking due to nutrient restriction or 
another cause; c) to provide the substrate for a downstream product of GalCer—i.e., ST, 
which might be made to alter cell migration, adherence, or recognition by other cells 
during states of ER stress; and d) to shift the category of glycolipids from GlcCer and its 
downstream metabolites to GalCer and ST, which might change the cell-cell 
communication, adhesion, etc.  These are just a few of the interesting possibilities for 
future study. 
It is hoped that this summary and these speculations illustrate some of the exciting 
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